Curriculum Vitae

Benjamin Wolozin, M.D., Ph.D.

Office Address: Boston University School of Medicine
Department of Pharmacology
72 East Concord St., R-614
Boston, MA 02118

Office Telephone: 617-358-1995

Email: bwolozin@bu.edu

Date of Birth: May 27, 1958

Place of Birth/Citizenship: Washington, D.C./ USA

Marital Status: Married, 2 children

EDUCATION

1976 - 1980	B.A. - Chemistry, Wesleyan University, Middletown, CT
1981 - 1988	M.D., Ph.D. - Neuroscience, Albert Einstein College of Medicine, New York, NY

PROFESSIONAL POSITIONS

1/2020 – present	Member, Neurophotonics Center, Boston University
5/2015 - present	Professor, Program in Neuroscience, Boston University
11/2011 – 5/2012	Physician, Geriatric Research and Education Clinical Center, Edith Nourse Rogers Memorial Veterans Affairs Center, Bedford, MA (5/8 FTE).
1/2008 – present	Joint Appointment, Professor of Neurology, Boston University School of Medicine
6/2004 – present	Professor, Department of Pharmacology Boston University School of Medicine 2005: Affiliated program memberships: Program in Biomedical Neuroscience Cell and Molecular Biology Program
8/2002 – 6/2004	Professor, Department of Pharmacology Loyola University Chicago Stritch School of Medicine
8/97 – 6/2004	Joint Appointment in the Neuroscience Program, and in the Molecular Biology Program, Loyola University Chicago Stritch School of Medicine
8/96-6/2004	Associate Professor, Department of Pharmacology Loyola University Chicago Stritch School of Medicine

8/90 -6/96	Commissioned Officer, PHS and Section Geriatric Psychiatry, Laboratory of Clinical Science, NIMH, NIH, Bethesda, MD
7/89 -6/96	Staff Fellow, Section on Clinical Neuropharmacology, Laboratory of Clinical Science, NIMH, NIH, Bethesda, MD
6/88 - 6/89	Postdoctoral Fellow, Mt. Sinai Medical Center, New York, NY
3/83 - 1/87	Graduate Thesis Research, Albert Einstein College of Medicine
9/80 - 6/81	Research Technician, Sloane Kettering Institute for Cancer Research
9/78 - 6/80	Undergraduate Thesis Research - Wesleyan University

INDUSTRIAL POSITION

2014 – present Aquinnah Pharmaceuticals, Inc.
Co-founder and CSO
Aquinnah Pharmaceuticals is a company whose mission is to develop novel medicines to treat neurodegenerative diseases, taking advantage of the biology of RNA binding proteins and the RNA translational system. www.aquinnahpharma.com

2001- 2004 Pi-Pets, LLC.
Founder, CEO and Vice-Chairman of the Board
Pi-Pets is a company whose mission is to produce transgenic ornamental fish. The company facilities are located on the grounds of Harbor Branch Oceanographic Institution, Ft. Pierce, FL.

HONORS

2017	Spivack Award, Boston University Distinguished Scholar in Neuroscience
2016	Aquinnah Pharmaceuticals Inc., "Most innovative company in neurodegeneration research, 2016", New Economy Magazine, World Media Group, London, England
2016	Fellow of the AAAS
2013	Zenith Award, Alzheimer Association
2013	Evans Center DOM Collaborator of the Year Award: Basic Sciences
2007	Memory Ride Award Recipient, Massachusetts chapter of the Alzheimer Association
2006	Fellow, Center for Skeptical Inquiry
2001	Alzheimer Research Forum Merit Award
2000	Loyola University Medical Center Graduate School Faculty of the Year

2000 Dept. of Pharmacology, Loyola University, Faculty of the Year

1993 A. E. Bennett Award, Society for Biological Psychiatry. This award is given for the best paper submitted to the award committee by an individual 35 yrs. of age or less. The winning paper is
presented at the annual society meeting.

1993 Commissioned Officer Commendation Award. This is an award given for meritorious service in the Public Health Service.

1988 Donald B. Lindsley Prize, Society for Neuroscience. This prize is awarded to the best graduate thesis oriented solving a problem in behavioral neuroscience.

1987 Honorable Mention, Sheard Sanford Award Competition, American Society of Clinical Pathologists. This competition is for the best paper in the field of clinical pathology published by an individual still in training (Ph.D or M.D.).

1981 Medical Scientist Training Program Fellowship (M.D. - Ph.D.) NSF Graduate Fellowship (Ph.D. -subsequently declined).

1980 Latin Honors: Magna Cum Laude (Wesleyan)
Departmental Honors: Chemistry
Hawk Prize - For excellence in Biochemical Research (Wesleyan).

PROFESSIONAL MEMBERSHIPS

Society for Neuroscience
American Society for Biochemistry and Molecular Biology
American Academy for the Advancement of Science
Foundation for Biomedical Research
Committee for Skeptical Inquiry (2006: Member of board of executives and Fellow of CSI)
Virtual Academy of the Targeted Proteins database (TPdb, 2008)

SERVICE

1998	Designed M.S.-M.B.A. and Ph.D.-M.B.A. programs
1998/9	Councilor, Chicago Chapter of the Society for Neuroscience
1999 -Present	Director, M.S.-M.B.A. program
	Director, Ph.D.-M.B.A. program
1999-2001	President, Chicago Chapter of the Society for Neuroscience
2000	Organized retreat for Loyola Molecular Biology Program
2002	Organizer for Alzheimer Social, Society for Neuroscience, Orlando, FL
2006 – Present	Executive Board, Center for Skeptical Inquiry
2006	Organizer for Alzheimer Social, Society for Neuroscience, Atlanta, GA
2006	Director of Advising, M.D., Ph.D. Program, BUSM
2006 – 2013	Executive Board, Center for Skeptical Inquiry, www.csi.org
2009-10	Alzheimer Prevention Board, Executive Committee
2011-13	Charleston Conference on Alzheimer's disease Awards Committee
2017 -2020	Society for Neuroscience, Public Education and Communications Committee

FUNDING

APOE Genotype Mediated Effects on Alzheimer Disease Risk and Mechanisms
Principle Investigators: Linday Farrer/Gyungah Jun/Benjamin Wolozin (MPI)
Type: NIH/NIA U01AG082665-01
Pending (sent to council by NIA admin)
07/1/2023 – 06/30/2028
$4,086,900

Nanobodies targeting stress granule components
Principle Investigator: Yongku Cho (PI, UConn)
Subcontract: Benjamin Wolozin (co-I)
Type: NIH/NIA R21AG083761-01
Pending (sent to council by NIA admin)
07/01/2023 – 06/30/2025

The role of N6-methyladenosine modified RNA in Alzheimer's disease
Principle Investigators: Benjamin Wolozin/Xiaoling Zhang (MPI)
Type: NIH/NIA 1R01 AG080810-01
12/15/2022 – 11/30/2027
$ 3,955,189

Exploring the Pathophysiology of AD and ADRDs with 3D Asteroid Models
Principle Investigators: Benjamin Wolozin/Christine Cheng (MPI)
Type: NIH/NIA 1R56 AG074591-01
9/1/2021 – 8/31/2022
$916,217

Circular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathology
Principle Investigators: Benjamin Wolozin/Xiaoling Zhang (MPI)
Type: NIH/NIA 1U01 AG072577-01
6/1/2021 – 5/31/2026
$2,033,253

Development of Synthetic Feedback Circuits to Prevent Tau Oligomerization
Principle Investigators: Benjamin Wolozin/Ahmad Khalil (MPI)
Type: BrightFocus Foundation
1/1/2020 – 12/31/23
$1,000,000

Synthetic Human Brain Studies
Principle Investigators: Benjamin Wolozin/Christine Cheng (MPI)
Type: BU Kilachand Fund for Integrated Life Sciences Engineering
9/1/19 – 8/30/2021
$500,000

Gene modifiers of protein interaction networks in tauopathy
Principle Investigators: Benjamin Wolozin/Andrew Emili (MPI)
Type: R01 AG064843-01, 8/1/19 – 7/31/24

$3,245,787

Systems-level functional proteomics analysis of synaptic assemblies in Alzheimer's disease and mouse models of tauopathy
Principle Investigators: Benjamin Wolozin/Andrew Emili (MPI)
Type: R01 AG061706-01, 2/15/19 – 11/30/24
$4,088,880

RNA Binding proteins as novel targets in Alzheimer's disease
Principle Investigator: Benjamin Wolozin
Type: 3R01AG050471-04S1
$245,654, 9/1/2018 – 4/30/2019
This proposal investigates the regulation of tau liquid liquid phase separation (LLPS) and fibrillization by RNA binding proteins (RBPs).

Regulation of brain neuroprotection and inflammation by TIA1
Principle Investigator: Benjamin Wolozin
Type: 1R21AG059925
$453,750, 8/15/2018 – 5/31/2020
This proposal generates conditional TIA1 knockout mouse lines for studying TIA1 biology.

Capturing the molecular complexity of Alzheimer's disease through the lens of RNA binding proteins.
Principle Investigator: Benjamin Wolozin/ Hu Li (MPI, Mayo Clinic)
Type: 1RF1AG056318-01
$3,944,412, 6/1/2018 – 2/28/2023

Stress Granule Inhibition in SARS-CoV-2 Infected Cells
Principle Investigator: Benjamin Wolozin
3RF1AG056318-01A1S1
$410,947, 9/8/2020 – 9/7/2021
This proposal investigates transcriptional signatures from varying types of Alzheimer's disease cases and animal models, to build molecular network models.

Inhibition of tau pathology in human neurons
Principle Investigator: Benjamin Wolozin
Foundation: Cure Alzheimer's Fund
$100,000, July 15, 2017 – July 14, 2018
This proposal explores the mechanism by which TIA-1 and phosphorylation contribute to aggregation of Tau protein in induced neurons from human donors.

"Targeting RNA metabolism and the stress granule Pathway to inhibit tau aggregation"
Principle Investigator: Benjamin Wolozin
Foundation: Thome Medical Foundation
$500,000), January 2, 2016 – Dec. 31, 2018
This proposal funds a high throughput screen to identify and develop compounds that inhibit tau aggregation following induction by the RNA binding protein TIA1.

"Interaction of tau with RNA binding proteins in Alzheimer's disease"
Principle Investigators: Benjamin Wolozin
Type: 1R01AG050471 (NIH)

$3,218,727 (in process), Sept. 1, 2015 – Aug. 31, 2020

This proposal examines how the microtubule associated protein Tau interacts regulates RNA metabolism in human brain, animal models of Alzheimer's disease and in cultured neurons.

"Post-translational modifications regulating pathological stress granules"
Principle Investigators: Benjamin Wolozin
Type: 1R01AG050471 (NIH), Administrativa Supplement
$88,476, Sept. 15, 2017 – April 30, 2018

"Regulation of Tau oligomerization by interaction with TIA-1"
Principle Investigator: Benjamin Wolozin
Foundation: CureAlz Fund
$100,000, July 1, 2014 – June 30, 2015
This proposal explores the mechanism by which TIA-1 and phosphorylation contribute to aggregation of Tau protein.

"TDP-43 aggregation inhibitors for the treatment of ALS"
Principle Investigator: Glenn Larsen/Benjamin Wolozin (Multi PI)
Type: 1R43NS095481-01
$682,000, November 9, 2015 – November 8, 2017
This proposal identifies small molecule compounds that can reduce the progression of TDP-43 pathology in mouse models of amyotrophic lateral sclerosis.

"Targeting Stress Granule Biology in Alzheimer's Disease"
Principle Investigator: Benjamin Wolozin
Foundation: BrightFocus Foundation
$250,000, July 1, 2015 – June 30, 2018
This proposal explores the role of novel RNA binding proteins, shown to bind tau, in the evolution of pathology in Alzheimer's disease and in animal models related to Alzheimer's disease.

"HDAC6, tau and stress granules"
Principle Investigators: Benjamin Wolozin/Leonard Petrucelli (Multi PI)
Type: R01 NS089544 (NIH)
$2,648,350, Sept. 1, 2014 – Aug. 31, 2019
This proposal examines the regulation of neurofibrilliary (Tau) pathology and stress granule formation by HDAC6 and acetylation in cultured neurons and in vivo.

"Regulation of RNA translation by MAPT in Alzheimer's disease"
Principle Investigator: Benjamin Wolozin
Foundation: CureAlz Fund
$100,000, July 1, 2015 – June 30, 2016
This proposal explores the regulation of mRNA localization and association by MAPT.

"RNA Binding Proteins in Alzheimer's disease"
Principle Investigator: Benjamin Wolozin
Foundation: BrightFocus Foundation
$100,000, July 1, 2014 – June 30, 2014
This proposal explores the role of novel RNA binding proteins, shown to bind tau, in the evolution of pathology in Alzheimer's disease and in animal models related to Alzheimer's disease.

"It Takes TIA to Tangle: The Role of RNA Binding Proteins in AD"
Principle Investigator: Benjamin Wolozin
Foundation: Alzheimer Association, Zenith Award

$450,000, January 1, 2014 - December 31, 2017
This proposal explores the mechanism by which TIA-1 and TTP contribute to formation of neurofibrillary tangles.

"Mechanism and therapy for tauopathy based on RNA binding proteins"
Principle Investigator: Benjamin Wolozin
Foundation: CurePSP Foundation
$150,000, August 1, 2013 - July 31, 2015
This proposal identifies small molecule compounds able to inhibit aggregation of tau protein promoted by RNA binding proteins.

"Target identification for TDP-43 inclusion inhibitors."
Principle Investigator: Benjamin Wolozin
Foundation: Massachusetts Neuroscience Consortium
$250,000, July 1, 2014 - June 30, 2015
This proposal functionalizes our TDP-43 inclusion inhibitors, and proposes to identify their targets of action

"RNA Binding Proteins in Alzheimer's disease"
Principle Investigator: Benjamin Wolozin
Foundation: BrightFocus Foundation
$150,000, July 1, 2012 – June 30, 2014
This proposal explores the role of the RNA binding protein, G3BP, in the evolution of pathology in Alzheimer's disease and in animal models related to Alzheimer's disease.

"Stress Granules and the Biology of TDP-43"
Principal Investigator: Benjamin Wolozin
Type: R01 (ES020395), Agency: NIH/NIEHS
$2,927,560, Mar 1, 2012 – Dec 31, 2016
The goal of this study is to elucidate the mRNA that bind TDP-43 in stress granules, and to determine whether stress granules contribute to the pathophysiology of TDP-43 in vivo.

Supplemental Award for ES020395: Co-PIs: Sherr (BU), Rademakers (Mayo)
Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER)
$1,188,000 Dec 1, 2013 – Dec 31, 2016

"Identification of compounds that inhibit aggregation and toxicity of TDP-43"
Principal Investigator: Benjamin Wolozin
Type: R21 (NS073679-01), Agency: NIH/NINDS
275,000, Oct. 1, 2011 – Sept. 30 2013
This proposal studies the relationship between TDP-43 and RNA inclusions termed stress granules.

"Probing the structure of TDP-43 Aggregation at the Nanoscale level"
Principal Investigators: Benjamin Wolozin (Pharm) and Amit Meller (BME) Agency: Boston University
$30,000 Type: Institutional Pilot Grant Period: December 1, 2009 – April 30, 2010
The objective of this grant is to use nanotechnology to investigate TDP-43 aggregation.

"The Role of Stress Granules in the Pathophysiology of TDP-43"
Principal Investigator: Benjamin Wolozin
Type: R21 (R21NS066108), Agency: NIH/NINDS
$275,000, April 1, 2010 – March 31 2012
This proposal studies the relationship between TDP-43 and RNA inclusions termed stress granules.

"LRRK2 and Neurodegeneration"
Principal Investigator: Benjamin Wolozin
Type: RO1 (R01NS060872) Agency: NIH/NINDS
$1,093,750 Feb 1, 2009 – Jan 31, 2014
This proposal studies how LRRK2 modifies the response of neurons to stresses associated with Parkinson's disease.

Supplemental Award for NS060872:
Opticogenetic Control of Mitochondrial Function
$81,244 Sep 1, 2010 – Aug 31, 2011

"Suppression of the heat shock response in aging and neurodegeneration"
Benjamin Wolozin (Co-PI; Michael Sherman, PI)
Type: R21 (NS049339) Agency: NIA, NIH
$234,750, Grant Period: July 1, 2008 – June 30, 2010
The objective of this grant proposal is to the role of p53 in the heat shock response in neurodegeneration.

"Identification of Inhibitors of TDP-43 pathology"
Principle Investigator: Benjamin Wolozin Agency: Harvard Center for Neurodegeneration and Repair
$60,000 Period: Nov 1, 2008 – Oct 31, 2009
This proposal funds a high throughput screen to identify compounds that inhibit TDP-43 pathology.

"Assessing the Potential for Angiotensin Receptor Blockers in Prevention and Treatment of Dementia"
Principal Investigator: Benjamin Wolozin Agency: Retirement Research Foundation
Type: Foundation Grant Period:
$160,000 Period: June 1, 2008 – May 31, 2009
The objective of this grant proposal is to determine whether angiotensin receptor blockers modify the risk of Alzheimer's disease.

"SirT1 activators as therapy for Parkinson's disease"
Principal Investigator: Benjamin Wolozin Agency: Michael J. Fox Foundation
$230,000 Type: Foundation Grant Period: June 1, 2008 – May 31, 2010
This proposal examines the efficacy of foxo-activating compounds in neuroprotection for Parkinson disease.

"LRRK2 interactions with pathways linked to protein folding and degradation"
Principle Investigator: Benjamin Wolozin Agency: Alzheimer Association
$240,000 Period: Oct 1, 2007 – Sept. 30, 20010

"Interaction Between Genes and the Mitochondria in Parkinson's Disease"
Principle Investigator: Benjamin Wolozin
Type: RO1 (1R01ES015567) Agency: NIH/NIEHS
$1,250,000 Period: Nov 1, 2006 – Oct 30, 2011
This proposal studies how genes implicated in Parkinson's disease affect mitochondrial function.

"Identification of Functional Inhibitors of LRRK2"
Principle Investigator: Benjamin Wolozin Agency: Harvard Center for Neurodegeneration and Repair

$60,000 Period: June 1, 2006 – May 31, 2007
This proposal funds a high throughput screen to identify compounds that inhibit LRRK2 activity.

"Identification of therapeutics that protect against toxins and genes implicated in Parkinson's disease via the Forkhead-mediated transcription pathway"
Principle Investigator: Benjamin Wolozin Agency: Michael J. Fox Foundation
$115,000 Period: June 1, 2006 – May 31, 2007

"Identification of Compounds that Inhibit Synuclein Aggregation"
Principle Investigator: Alan Snow, Proteo Tech Agency: Michael J. Fox Foundation
Type: Foundation Grant Period: January 1, 2006 – December 31, 2008
Direct: $208,084 Total: $272,113

National Parkinson's Foundation, 7/1/05 – 6/30/06, Parkin function in human lymphoblasts, Direct: $100,000; Total: $100,000.

Fidelity Foundation, 1/1/05 – 12/31/06, Identification of Medicines that Alter the Risk of Alzheimer's disease. Direct: $225,000; Total: $225,000.

Pfizer, 12/1/02 – 11/30/03, (Co-PI), Assessment of the association between the development of Alzheimer's disease and surgical interventions. Direct: $23,321; Total: $26,819

NIH RO1, 6/1/01 – 5/31/06, Regulation of Ubiquitination and Receptor Signaling by Parkin (NS41786-01) Direct: $1,125,000; Total: $1,710,000

US Army Medical Command, 9/1/01-8/30/06, Mechanisms of α-synuclein aggregation and toxicity. (DAMD17-01-1-0781). Direct: $630,558; Total: $933,355

NIH RO1, 8/01/01 – 7/31/06, Regulation of APP processing by presenilins, (AG/NS17485-01A2). Direct: $1,150,000; Total: $1,784,000

Panacea Pharmaceuticals, 1/1/2002 – 12/31/2004, Identification of Pharmaceuticals to Prevent α-Synuclein Aggregation and Toxicity, Direct: $150,000; Total: $232,500. (Terminated as of 2003 due to financial difficulties at Panacea).

Fukuoka University, Fukuoka Japan, 2/1/1999 – 1/31/02, Mechanisms of β-Amyloid Toxicity
Direct: $27,000; Total: $30,000

Retirement Research Foundation, 1999-2001, α-Synuclein: A Key to Parkinson's Disease,
Direct: $ 133,204 Total: $148,004

Falk Foundation, 1999-2000, Identifying Genes Involved in Autism, Direct: $20,000

Alzheimer Association, 1999-2002, A role for presenilin 2 in the processing of amyloid precursor protein,
Direct: 162,000, Total: $180,000

National Parkinson Foundation, 1998, α-Synuclein-mediated Cell Death, Direct: $29,997

Neuroscience and Education Foundation, 1997, Programmed Cell Death in Neurons and Immune Cells: Actions of Wildtype and Mutant Presenilin-1. Direct: $54,545; Total: $60,000

Pfizer Foundation, 1997, Studies of Olfactory Neuroblasts. Direct: $35,714; Total: $45,000

Loyola University Potts Funds: 1996, Direct: $375,000

Molecular Geriatrics, 1993-5, $180,000

Sandoz Foundation for Geriatric Research, 1991-2, $30,000

Graduate students funded by individual NRSA grants from NIH:

L. Petrucelli		(1998-01, # 1 F31 MH12297)
J. Palacino		(1999-02, # 1 F31MH12479)
P. Choi		(2000-03, # 1 F31MH12764)
H. Snyder		(2002-05, # 1 F32NS42510)
D. Chan		(2010-13 # 1 F30NS066658)
T. Vanderweyde		(2012 – 14, #1 F31AG042213)
D. Taub	(Co-Mentor)	(2015 -)
N. Yazdani	(Co-Mentor)	(2016 - 2017)
B. Maziuk		(2018 -) F31NS10675

POSTDOCTORAL TRAINEES:

Name:		Current Position:
Liang Zhang, Ph.D.	1992-3	Asst. Prof., University of Hong Kong
Yongquan Luo, Ph.D.	1994-6	Staff Fellow, NIA
Katsunori Iwasaki, Ph.D.	1995 – 1996	Ass. Professor, Dept. of Pharmacology, Fukowa University, Japan
Junxin Chen, Ph.D.	1999 – 2000	Postdoctoral Fellow, Northwestern University
Jialin Zhang, M.D.	2001 – 2003	Postdoctoral Fellow, Cleveland Clinic
James Brown, Ph.D.	2002 – 2004	Postdoctoral Fellow, Loyola University
Joanna Cordy, Ph.D.	2005 – 2008	Research Advisor, Kings College
Jong-Ho Peter Lee, Ph.D.	2009 – 2010	Scientist, Proteostasis, Inc., Boston, MA
Julien Dusonchet, Ph.D.	2011 – 2014	(Co-mentored with Jim Collins, HHMI) Welding GmbH, Project Manager (Germany)
Katie Youmans, Ph.D.	2011 – 2015	Medical Scientist Liason, Genentech
Peter Ash, Ph.D.	2013 – 2022	Senior Scientist, Aquinnah Pharmaceuticals Inc.

Heather Balance, Ph.D.	2016 – 2018	Postdoctoral Fellow, U. Pittsburgh
Lulu Jiang, M.D,, Ph.D.	2017 – Present	Research Assistant Professor, Boston University
Mamta Verma, Ph.D.	2018 – 2021	Scientist, UMass Medical Center
Jenifer Shattuck, Ph.D.	2018 – 2019	Scientist, Cell Systems, Inc.
Zhuo Yang, Ph.D.	2020 – 2021	Postdoctoral Fellow, Harvard University
Sambhavi Puri, PhD.	2021 – Present	
Sophie van der Spek	2022 – Present	

GRADUATE STUDENTS:

(The " * " denotes winners of the Russek Day Award, which is given to the one outstanding student in the Boston University Dept. of Pharmacology each year).

James Palacino	1997-2001	Principal Scientist, Novartis
		Thesis Project:Regulation of APP Processing by Presenilins and the WNT pathway
	Prior Education:	Providence College, BA 1997
Leonard Petrucelli	1998 – 2000	Professor, Chair
		Dept. Neuroscience, Mayo Clinic Jacksonville, FL
	Thesis Project:	The Effect of Beta-Amyloid on Neurotrophin Receptor Cell Signaling In Alzheimer's Disease
	Prior Education:	Barry University, BA 1992
Natalie Ostrerova	1998 – 2001	Director of Cell Biology Services, Becton Dickinson Labs.
	Thesis Project:	α-Synuclein: Biology and Pathophysiology in Parkinson's disease
	Prior Education:	University of Odesa, BA 1998
Peter Choi,	1998 – 2003	Deceased
		Previously: Resident, U. Washington
	Thesis Project:	Regulation and Function of the Parkin Protein
	Prior Education:	Cornell University, BA 1996
Mark Frasier	2000 – 2004	Vice President, Michael J. Fox Foundation
	Thesis Project:	Induction of proteins implicated in Parkinson pathology by α-Synuclein
	Prior Education:	University of Dayton, BA 2000
Heather Snyder	2000 – 2004	Director for Research, Alzheimer Association
	Thesis Project:	Interaction of α,β and γ-synuclein with the proteasome
	Prior Education:	University of Virginia, BA 2000
Rina Ved	2001 – 2004	Sales Associate, Medicorp
	Thesis Project:	Using C. elegans to examine the mitochondrial effects of proteins implicated in familial Parkinson's disease
	Prior Education:	Georgetown University BA 2000
Cindy Hsu*	2004 – 2008	Assistant Professor

		Dept. of Emergency Medicine, University of Michigan
	Thesis:	Cross-talk between LRRK2 and MAPK in Parkinson's Disease (Pharmacology Russek Award Winner)
	Prior Education:	Johns Hopkins University, BA 2002
Gary Yue	2004 – 2006	Masters Student
	Prior Education:	Shanghai Institute of Biochemistry, MS 1990
Maria Guillily*	2006 – 2011	Instructional Designer, Mark Morris Institute
	Prior Education:	University of Rochester, BA 2005 (Pharmacology Russek Award Winner)
Misha Riley	2006 – 2008	Former Graduate Student (switched to Oceanography)
	Prior Education:	University of North Carolina, BA 2005
Liqun Liu*	2007 – 2010	Merck, Senior Scientist
	Prior Education:	University of Massachusetts, BA 2005 (Pharmacology Russek Award Winner)
Andrew Ferree	2007 – 2013	M.D., Ph.D., Resident, Boston University School of Medicine
	Prior Education:	Wheaton College, BA 2005
Diane Chan	2007 – 2011	Clinical and Research Fellow, Picower Institute, MIT Ass. Professor, Neurology, Massachusetts General Hospital
	Prior Education:	Cornell University, BA 2004
	Thesis:	LRRK2 and HDAC6: Directing Traffic at the Crossroads between autophagy, translation and neurodegeneration
Atsushi Ebata	2009 – present	Lab Systems Engineer, Lab Information Systems
	Prior Education:	Cornell University, BA 2007
Tara Vanderwyde*	2010 – 2015	Senior Manager, Customs, Biogen
	Prior Education:	Elmira College, BA 2009 (Pharmacology Russek Award Winner)
Joon Boon	2011 – 2016	Johns Hopkins U. (Med Student)
	Prior Education:	Boston University, BA 2009
Chelsea Trengrove	2011- 2016	Empatica Inc., Project manager
	Prior Education:	University of Colorado, BA 2010
Dan Apicco*	2013 – 2017:	Senior Scientist, AbbVie
	Prior Education:	Northeastern, BA 2012 (Pharmacology Russek Award Winner)
Alissa Frame	2014 – 2016:	Current Medical Student, M.D., Ph.D. program
	Prior Education:	Middlebury, BA 2007
Brandon Maziuk*	2015 – 2019:	Scientist, Dicerna Pharmaceuticals
	Prior Education:	Cornell University, BA 2014 (Pharmacology Russek Award Winner)
Chelsea Webber	2019 – present	Current Graduate Student
	Prior Education:	Simmons College, BA 2014
Alejandro Rondon Ortiz	2020 – present	Current Graduate Student
	Prior Education:	University of Peru, BA 2019
Hannah Rickner	2020 – 2023	Principle Scientist, Fluent Biosciences
	Prior Education:	University of Vermont, BA 2014
Jenna Libera	2021 – present	Current Graduate Student
	Prior Education:	Clark College, BA 2020
Raven Gounsolin	2023 – present	Current Graduate Student
	Prior Education:	U. Mississippi, BA 2022

Masters Students:

Jules Mangels	2006
Joel Lanceta	2008
Christy Leonard	2008
Katie Gliditsch	2008
Tapan Mehta	2009
Katelyn Smith	2010
Laura Adams	2010
Lauren Richter	2010
Havisha Karnam	2010
Vivek Gowda	2010
David Kruse	2010
Marisa Feiler (Univ. Ulm, Germany)	2011
Isaac Goldzer	2012
Hao Wang	2014
Katarina Kozial	2023

Undergraduate Students:

Nora Pyenson	2008 – 2011
Kyle Thibodeau	2009 – 2010
John Batoha	2010 – 2011
Maria Iuliano	2010 – 2013
Monica Genji	2010 – 2012
Jennifer Watson	2012 – 2013
Nancy Zacharakis	2012 - 2013
Joanna Kizmal	2013 - 2014
Emily Botelho	2014 – 2016
Amanda Jeh	2015 – 2017
Bria Adams (URM)	2015 – 2017
Brandon Bedell	2016 – 2016
Robson Ali	2016 – 2018
Marcello Orlando	2017 - 2019
Emily Van Vlet	2016 – 2021
Grace Wallick	2016 – 2019
Anna Lourdes Flores Cruz	2017 – 2021
Shuwein (Eric) Lei	2018 – 2020
Estefania Obando	2018 – 2020
Louloua Al-Mohanna	2018 – 2019
Bryce Mashimo	2018 – 2020
Carl Li	2018 – 2020
Jane Kim	2019 – 2020
Caroline Murphy	2020 – 2022
Nicole Papazian	2020 – 2022
Michelle Wong	2021 – 2022
Klyve Otinkorang	2021 – Present
Angela Zhang	2021 – Present
Tuyet-Anh Nguyen	2021 – Present
Jenny He	2022 – Present
Elena Kelly	2022 – Present

Quince Young		2022 – Present
KK Jiang		2022 – Present
Alper Kilci		2022 – Present
Thuc Nhan Tran		2022 - Present

Ph.D. Dissertation Advisory Committees: (Excluding Students in the Wolozin Lab)

Aaron Winkler		2004 - 8
David Eyerman		2004 - 8
Katie Famous		2005 – 8
Sonia Podvin		2005 – 8
Dan Roberts		2005 – 8
Kristen Bushell	Chair	2006 – 10
Nicole Fazo	Chair	2006 – 11
Julia Kim	Chair	2006 – 12
Nichole Piche-Nicholas		2006 – 13
Amy Robinson	Chair	2006 – 13
Sonia Podvin	Chair	2007 – 10
Pauline So		2007 – 10
Patty Bedard	Chair	2007 – 11
Sun Oh		2007 – 9
Matthew Whitaker	Chair	2008 – 10
Tara Stewart	Chair	2008 –10
Earl Gillespie	Chair	2008 –10
Meaghan Cappollucci	Chair	2008 – 15
Catherine Wei		2008 – 11
Guenwon Kim		2009 – 12
Tracey Tucker	Chair	2009 – 13
Rebecca Benham	Chair	2010 – 12
Johanna Crimins		2010 – 12
Robert Freilich	Chair	2010 – 13
Larissa Estrada	Chair	2010 – 15
Audrey DeMauro	Chair	2011 – 15
Kendra Kobrin	Chair	2011 – 15
Melissa Thompson		2011 – 14
Marie Pierre-Payan	Chair	2012 – 15
Megan Varnum	Chair	2013 – 15
Elizabeth Stanford		2013 – 15
Michael Nagle		2013 – 15
Kelli Cox	Chair	2013 – 16
Lisa Goldberg	Chair	2013 – 17
Andrew Hoss	Chair	2014 – 16
Neema Yazdani		2014 – 17
Julia Guzova	Chair	2014 – 19
Leah Kressin-Rea	Chair	2014 – 18
Eli Shobin		2015 – 19
Zohar Weinstein	Chair	2015 – 18
Daniel Taub		2015 – 18
Margarita Tararina	Chair	2016 - 20
Michael Romano	Chair	2016 – 18
Jeremy Burns		2017 - 21

Rekha Raghunathan		2017 - 19
Qiu Ruan		2017 – 2021
Chelsey LaBlang		2017 –2021
Eric Brownhill		2017 - 2021
Kate Henry	Chair	2017 - 2022
Christina Gallo	Chair	2019 –2022
Andrew Martin		2019 –2023
Shawn Herron	Chair	2019 –2022
Lucy Peterson	Chair	2021 –
Jean Royce Gatdula		2022 –
Michelle Nguyen	Chair	2022 –
Ana Vitantonio	Chair	2022 –
Chinyere Kemet	Chair	2022 –
Stanley Goldstein		2022 -

MAJOR COMMITTEES:

National:

Society for Neuroscience 2018 - 2021
Public Education and Communications Committee

Boston University:

Academic Standards Committee (Chair) 2022 - present
Boston University Graduate Medical Sciences

Boston University Strategic Plan: 2020 - present
Research That Matters

Committee on Faculty Conflicts of 2017 - present
Interest

Committee on Basic Life Sciences 2016-2017
At Boston University

University Council Committee 2016-present
on Research and Scholarly Activities

Pharmacology Chair Search Committee 2021

Neurology Chair Search Committee 2016

Pharmacology Search Committee (Ch) 2021
Biology Faculty Search Committee 2021 -
Anatomy Faculty Search Committee 2016 – 2020

M.D., Ph.D. Director Search Committee 2015-2016

Core Oversight Committee: Co-Chair 2014 – present
(Dept. of Medicine)

Provost Misconduct Committee 2015

M.D.-Ph.D. Advising: Director 2006 - 2010

M.D.-Ph.D. Steering Committee 2005 - 2010

M.D.-Ph.D. Working Group, Director 2004 – 2010

M.D.-Ph.D. Admissions Interviewing panel 2004 - present

Executive Committee 2014 – present
BU Alzheimer's disease center

BioSample steering committee 2005 – 2014
BU Alzheimer's disease center

Pilot Grant Review Committee 2015 – present
BU Alzheimer's disease center

Boston University Alzheimer Development Board
2007 – 2012

Graduate Education Committee 2005 – 2021
(Pharmacology)

Qualifying Exam Committee 2009 – 2014
(Molecular Medicine)

Faculty Search Committees 2010 – present
- Addiction 2010 – present
- Cancer (Chair) 2010 – 2013
- Cardiovascular 2010 - 2012
- Emerging Technologies 2013-2015
- Neurology Chairman 2015
- Anatomy/Neurobiology Dept. 2016-20
- Neurodegeneration (Pharmacology (Chair) 2021
- Biology 2021
- Pharmacology Chairman 2021

High Throughput Screening Oversight Committee 2011 – 2015

T32 AD training grant executive committee 2010 – present

<u>Loyola University</u>:
M.D.-Ph.D. Steering Committee 1997 – 2004

Director, M.S.-M.B.A. program 1998 – 2004

Director, Ph.D.-M.B.A. program	2000 – 2004
Central Curriculum Authority Design Subcommittee	2001 – 2004
Neuroscience and Aging Institute Executive Committee	2002 – 2004
Stritch School of Medicine Admissions Committee	1998 – 2001

SERVICE (GRANT REVIEWS):

Thome Medical Foundation, Chair	7/2019 – 7/2022
NIH PO1 review ZAG1 ZU1: Chair	4/2019
DFG (Germany) Program Review	11/7-8/2018
NIH Program Project Review: Chair	09/2016
NIH MDCN-T & V: Chair	08/2016, 06/2020
NIH New Chair Orientation: Presenter	08/2014
Invited Video submission for training	07/2019, video now posted on web by NIH CSR
NIEHS SEP	12/2014
CMND	2/10, 10/18, 3/20, 11/20
Standing Member	6/2011 – 2017
Chair	10/13 – 6/2015
CNNT	2/08, 2 & 10/09
ZNS1 SR-J(11) R35 Review	5/2016, 6/2017
ZRG1 MDCN-T(56)	6/2016, 6/2017
ZRG1 BDCN – Y(04)	10/08 (Chair), 7/2009 (Chair)
ZRG F03 N20	11/2019, 11/2022
CND Study Section	6/2006
Udall Center Study Section	7/2005; 10/2005; 4/12; 8/2014
BDCN3/CDIN Ad Hoc	6/0202; 6/2003; 3/2004; 10/2004; 2/2010
Standing Member	1/05 – 12/09
Acting Chair	10/07
NSDB Ad Hoc	2/02; 2/03
NLS1 Special Emphasis Panel	8/97, 4/98, 9/01
NLS1 Program Project review	10/97, 6/98
MDCN-1/A Ad Hoc	8/98, 9/99, 12/02; 4/04, 10/10
VA Merit Award Panel	8/2000
Alzheimer Association & AAIC	1997 – present
BrightFocus Foundation	2017, 2020
AFTD	2018 - present
Canadian Alzheimer Association	2011-13
Michael J. Fox Foundation	9/01; 9/06, 6/2010, rapid reviews continuing
GW Weston Foundation	2/2014 – 2018
Charleston Conference on AD	3/2012-3/2014
Florida Biomedical Research Program	2016 – present
MRC Reviews (UK)	2017
AFTD	2016 – present

Action on Hearing Loss	2017
Israel NSF	2016 -

JOURNAL REVIEWING (AD HOC):

Nature Medicine, Neuroscience, Aging	New England Journal of Med.	Lancet
Nature Neuroscience	Neuron	Nature Communications
Journal of Biological Chemistry	Science Translational Med.	Journal of Neuroscience
Molecular Psychiatry	Experimental Neurology	Science Reports
Cell Reports	Molecular Cell	Developmental Cell
Neurology	Annals of Neurology	Trends in Cell Biology
Brain Research	Biological Psychiatry	Archives Psychiatry
Neuroscience	PNAS	Neurochemical Res.
Neurobiology Disease	American J. Pathology	J. Cell Biology
J. Neurochemistry	Biochemistry	British Medical Journal
European J. Neurosci	Trends in Biochemistry	FEBS
EMBO	EBIOM	Neuroscience
Molecular Neurodegeneration	Journal of Alzheimer's Dis.	Alz Res & Ther
iScience	eLIFE	

JOURNAL BOARD OF EDITORS:

PLosONE	July 2010 - 2011
Journal Biological Chemistry	July 2003 – 2008; July 20010 – 2015
Neurodegeneration	2002 - 2014
Neurochemical Research	2000 – 2004
Current Alzheimer Research	2005 - 2014
Alzforum (Scientific Advisory Board) (www.Alzforum.com)	2000 – 2010
Neurotransmitter (Editor) Newsletter of the Loyola Neuroscience and Aging Institute)	2002 – 2004
Journal of Alzheimer's Disease	1998 – 2000, 2005

CONSULTING:

AbbVie	2017
Medivation	2016 – 2018
Novartis	2010
Ariad Pharmaceuticals	2009 - 2012
Collaboration:	2009 - 2011
Sirtris/Glaxo:	2008

	Collaboration:	2008 - 2009
ProteoTech	Member SAB	2010 – 2015
	Collaboration:	2006 - 2009
CMD Biosciences (Member of SAB)		2009 - 2014
Link Pharmaceuticals		2009
Johnson & Johnson		2007
CombinatoRx		2007 - 2008
Pharmacia		2002 - 2004
Abbot Laboratories		1986-1990
Cambria Biosciences		2004 - 2009
Pfizer		1997 – 2004
Eli Lilly		2005, 2007
Merck		2005 - 2007
Nymox		1998 – 2000
Panacea		1999 - 2003
Museum of Science and Industry, Chicago		1999 - 2000

COURSE LEADERSHIP

RNA metabolism and Neurodegeneration Diseases, Dept. of Chemistry, University of New Delhi, India	2018
Abnormal Proteins in Alzheimer's Dis.	2021 - present
Translational Genetics and Genomics	2016 - present
Design of Research Proposals/ Technical and Professional Skills in Pharmacology	2010 – present
Systems Pharmacology and Therapeutics (Course Director)	Fall, 2004 – present
Organ Systems Diseases	Spring, 2008 - present
Neurodegeneration (Pharm 406)	Spring, 1997 - 2004

Molecular Biology Journal Club Fall 1998 - Spring 1999

Methods in Molecular Pharmacology Summer, 1998 - 2004

Biotechnology Spring, 2000 – 2004

Therapeutics and Pharmacology August, 2001 – 2004
(Medical School 2nd Year Therapeutics Course)

COURSE PARTICIPATION

Mechanisms of Neurodegeneration 2016, 2019
University of Minho, Braga, Portugal
Molecules to Molecular Therapeutics: Spring 2105 – present
(Designed and co-taught 6 course segment on Alzheimer disease)
Foundations in Biomedical Sciences: Spring – 2012 – present
Translational Genetics and Genomics subsection

Research Proposal Workshop Spring 2010 – present
(Designer, Course Manager & Lecturer)

Advanced General Pharmacology Fall, 2004 – present
(Renamed Systems Pharmacology)
(Course Manager & Lecturer)

General Medical Pharmacology Fall, 2004 – present
(Medical School and Dental School)
(Renamed DrugsRx)

Responsible Conduct of Research (RCR) 2010, 2012, 2015 - present

Molecular Neurobiology and Pharmacology Fall, 2005 – present

Neurodegeneration 1997 – present

Unmet Medical Needs and Translational Solutions 2014
(Harvard Medical School)

Integrated Problems 2006 - 2010

Protein Folding 2007 – present

Inflammation and Disease 2007 – present

Molecular Medicine Journal Club 2008 - present

Molecular Biology Journal Club 1998 - 1999

Methods in Molecular Pharmacology 1998 - 2004

Biotechnology 2000 – 2004

Therapeutics and Pharmacology 2001 – 2004
(Medical School 2nd Year Therapeutics Course, Loyola)

Biochemistry and Molecular Biology Spring 1998 – 2004

Principles of Pharmacology Fall 1997 – 2004

Applied Principles of Pharmacology Fall 1997 – 2004

Receptor and Molecular Pharmacology Spring, 1998 – 2004

Introduction to Pharmacology Spring, 1998 – 2004

ACADEMIC INNOVATION

PhD Program:

Wikipedia in Education: (Dept. of Pharmacology, BU) In 2017, With the help of WikiEDU, I incorporated Wikipedia Editing into my Systems Pharmacology class. As the term project, students identify a Wikipedia page that needs more content and is related to pharmacology. The students then craft a new page as their term paper project. Following my review and grading, the students upload the page to Wikipedia. This approach is being extended throughout BU through Wikipedia workshops that are being organized by the BU Library Services.

Designed Research Development Workshop: (Dept. of Pharmacology, BU) In 2010, I was instrumental in redesigning the structure of the qualifying exam process for the Dept. of Pharmacology. This redesign has students prepare a NRSA styled grant application for their qualifying exam and placed our department at the forefront of a trend that has extended to most other basic science departments at the medical center. In making the change, I created the "Design of Research Proposals Workshop" to provide a semester long course that teaches them how to write grant proposals and, more generally, teaches them how to think about the design of research projects.

Systems Pharmacology and Therapeutics (SPT1 & 2): (Dept. of Pharmacology, BU) I took over directorship of this course when I joined the Dept. of Pharmacology in 2004. Before I joined the department the course was named "Advanced General Pharmacology" and was a minor course (2 credits/semester), in which faculty presented their research interests. I renamed and comprehensively redesigned the course with the goal of providing a signature course that would give a comprehensive overview of the mechanisms of action of all the major classes of pharmaceuticals. The number of course credits for the course increased from 2 to 4 credits to reflect the enhanced breadth and depth of the class. The increasing importance of this course is reflected by the departmental decision to expand into a yearlong course, in which the students receive 4 credits each semester (at my request, the second semester course, SPT2 is directed by two other faculty members).

In addition to greatly enhancing the breadth and depth of SPT, I have also contributed educational innovations that have been adopted by other graduate courses. I incorporated a challenge

component to each class in which student break out into small groups that each answer a different current research question that incorporates the material that they just learned but for which the correct answer is genuinely not known. The students then present their answers to each question to the class, and the other class members critique the answers. This structure was inspired by the medical model of "see one, do one, teach one".

In 2017 I incorporated an additional innovation. Previously students were required to submit a term paper for the course on a pharmaceutical subject related to the course material. As of 2017, the students now must create or edit a Wikipedia page related to pharmacology. The students are graded on the quality of their Wikipedia page. This work is done in conjunction with the official "Wiki-education program", utilizes advisors from Wikipedia, involves peer review by class members, and ultimately is reviewed by the editors of Wikipedia. This program provides a benefit to the students by giving them a task that represents a genuine contribution to society extending well beyond their immediate course contribution, and benefits Wikipedia and society by increasing the scope, depth and citations of Wikipedia pages.

Molecules to Molecular Therapeutics (Dept. of Medicine, BU): I worked with Bob Stern to designed an innovative 6 course segment (in Bill Cruikshank's Mol. To Mol. Therapeutics Class) that uses basic integrated basic science/ clinical science classes to teach students about the design of clinical trials for Alzheimer's disease.

MD, PhD program: (BU) Joined the existing program as the senior faculty advisor at Boston University School of Medicine. Instituted numerous changes including hiring a dedicated administrator, initiating a graduate phase clinical clerkship, initiating a faculty/student advisor meeting, expanding the MD, PhD student forums with formal inclusion of social, research, clinical and career seminars, and creating a new MD, PhD website at BU.

BU PD Forum: (BU) Initiated an annual meeting at Boston University School of Medicine that brings together researchers interested in Parkinson's disease to brainstorm about novel approaches to Parkinson's disease.

Neurodegeneration: (Loyola)

I developed this course at Loyola in collaboration with Nancy Muma and Jack Lee. The course covers the molecular, biochemical and pathologic changes associated with neurodegenerative disorders.

M.S./ M.B.A. Program: (Loyola)

This is a dual degree program that I have developed (in collaboration with Israel Hanin, John Kostolansky, Luke Van de Kar, Sheryl Beck and Bill Wolfe), which offers students a Masters degree in Pharmacology and a Masters Degree in Business Administration.

Ph.D./M.B.A. Program: (Loyola)

This is a dual degree program that I am developing (in collaboration with Israel Hanin, John Kostolansky, Luke Van de Kar, Sheryl Beck and Bill Wolfe), which offers students a Doctor in Pharmacology and a Masters Degree in Business Administration.

Biotechnology: (Loyola)

This was a new course designed for the M.S./M.B.A. students designed to give them an introduction into the biotechnology and pharmaceuticals industries. Students use the following books at texts: "The Insiders Guide to the Biotechnology and Pharmaceutical Industry", "Strategic

Planning in the Biotechnology and Pharmaceutical Industry" and "Business Plan Pro". The course also brings in outside speakers from industry.

Bio-informatics Group: (Loyola)
This is an informal gathering of students and faculty at Loyola who gather once a month to discuss and work with problems in bio-informatics

Pharmacology Excellence in Science Poster Competition: (Loyola)
This is a poster competition at Loyola that provides undergraduate students an opportunity to present there research accomplishments in an academic setting.

WEB SITES DESIGNED

Loyola Dept. of Pharmacology	www.meddean.luc.edu/lumen/DeptWebs/pharm/index.htm
Loyola M.D.-Ph.D. Program	www.meddean.luc.edu/ssom/studres/mdphd/index.htm
Chicago Society for Neuroscience	www.beemnet.com/chicago
Boston University School of Medicine, M.D., Ph.D. Program	www.bumc.bu.edu/Dept/Home.aspx?DepartmentID=393
Wolozin Laboratory Web Site	https://sites.bu.edu/wolozinlab/
Aquinnah Pharmaceuticals Inc.	www.aquinnahpharma.com

Symposia Organized:

10/2022	Engineering the Brain from Discovery to Clinical Applications, Boston University, Boston, MA, 2022
07/2022	Contributions of Phase Separation to Neurodegenerative Disease, Alzheimer Association International Conference, San Diego, CA
06/2020	RNA-protein interplay and stress granules: key hotspots for the biology and disease of the brain
07/2019	Stress Granules in Neurodegeneration, Invited symposium Chair and organizer, Alzheimer Association International Conference, Los Angeles, CA, July, 2019
2/2018	New Discoveries in Treatment of Neurodegenerative Diseases, AAAS annual meeting, Austin, TX February, 2018
4/2005-15:	Boston University Parkinson's Disease Forum (every two years)
11/2011	Society for Neuroscience, mini-symposium: Translational Control at the Synapse and in Disease.

RECENT INVITED ACADEMIC LECTURES

Pending

Past

1. Mechanisms of Neurodegeneration in Alzheimer's disease: Tau, the translational stress response and the epitranscriptome. Mayo Clinic, Jacksonville, FL, January, 2023
2. Mechanisms of Neurodegeneration in Alzheimer's disease: Tau and the translational stress response, University of Kentucky, Lexington, KY, November, 2022
3. Tau, RNA Metabolism and the Stress Response, Science Webinar: Stress Granules: Deciphering the connections to neurodegeneration. November, 2022
4. Key Factors Driving Neurodegeneration in Alzheimer's disease: Tau, RNA metabolism and the Stress Response. Albert Einstein College of Medicine, The Bronx, NY, September 2022
5. Targeting Stress Granules for ALS and Alzheimer's disease, Cambridge Health Institute, Cambridge, MA, October, 2022
6. Tau phase separation: from basic biology to disease therapy. Session co-chair: Emerging Concepts in Basic Science: Contributions of Phase Separation to Neurodegenerative Disease, AAIC 2022, San Diego, CA, August, 2022
7. Frontotemporal dementia and ALS Mechanisms: Discussion Leader, Gordon Research Conference on the Neurobiology of Disease, Castelldefels, Spain, August, 2022
8. RNA methylation identifies novel regulatory networks and mechanisms in tauopathies, Gordon Research Conference on the Neurobiology of Disease, Castelldefels, Spain, August, 2022
9. Methylated RNA and the transcriptome: Hidden factors directing the stress response and tauopathy, ADPD2022, Barcelona, Spain, March, 2022
10. Interactions between tau, membraneless organelles and RNA metabolism in Alzheimer's disease, UCSD, (Virtual), March 2022.
11. The interface between Tau, RNA metabolism and stress that drives Alzheimer's disease, USF, January 2022.
12. Hidden factors directing the stress response, tau biology and Alzheimer's disease: Methylated and circular RNA. Boston University, RNA Club. December 2021.
13. Engaging the University Community with Wikipedia Curating and Creation (panel chair), National Wikipedia Conference, (Virtual), 2021
14. The interface between Tau, RNA metabolism and stress that drives Alzheimer's disease, NYU/Langione (Virtual), Sept. 2021
15. Biological interplay between Tau, RNA binding proteins and RNA metabolism in the Pathophysiology of Alzheimer's disease, UTMB and UFL, (Virtual), June 2021.
16. Biological interplay between Tau, RNA Binding Proteins and Membraneless Organelles in the Pathophysiology of Alzheimer's disease, University of Minnesota, (Virtual), October, 2020
17. Neurobiological support for MAPT (Tau) and other genes in the neuronal signaling pathway: Insights into novel pathways for disease therapy. AAIC Genetics Global Summit, September, 2020
18. Dysregulation of Protein Synthesis in Neurodegeneration, Invited symposium Chair, Alzheimer Association International Conference, Digital (Amsterdam, Netherlands), July, 2020
19. Biological interplay between Tau, RNA Binding Proteins and Membraneless Organelles in the Pathophysiology of Alzheimer's disease, Digital Conference, Turning Points: From Healthy Cells and Systems to Neurological Disease States, July, 2020

20. The role of RNA binding proteins in the pathophysiology of Alzheimer's disease: insights into novel pathways for disease therapy, FENS Summit, Digital (Glasgow, Scotland), July, 2020
21. Biological Interplay between Tau, RNA binding proteins and Membrane-less Organelles in the pathophysiology of Alzheimer's disease. Baylor College of Medicine, Houston, TX, October, 2019
22. Environmental risk factors for neurodegenerative disease. Shendong University, Shendong, China, September, 2019.
23. The role of RNA binding proteins in the pathophysiology of Alzheimer's disease: Insights into novel pathways for disease therapy. ECNP Congress, Copenhagen, September, 2019
24. Stress Granules in Neurodegeneration, Invited symposium Chair and organizer, Alzheimer Association International Conference, Los Angeles, CA, July, 2019
25. Alzheimer's Disease: Many Failed Trials so Where Do We Go from Here? Experimental Biology, Orlando, FL, April, 2019
26. The role of tau in Alzheimer's disease. Boston University Alzheimer's disease center. March, 2019.
27. Membrane-less organelles and RNA binding proteins as targets for therapy of neurodegenerative diseases. Boston University/Biogen Symposium: Innovations in Neuroscience Drug Discovery. Nov. 2018
28. Tau, RNA metabolism and the pathophysiology of Alzheimer's disease. SFN Satellite pre-meeting: RNA binding proteins and neurodegeneration, San Diego, CA, Nov 2018
29. Membrane-less organelles and RNA binding proteins: The biological underpinnings of neurodegeneration. World Congress Genedis 2018, Toronto, CA 2018
30. Stress Granule Formation and Neuronal Death, Alzheimer Association International Conference, Chicago, IL, July, 2017.
31. Membrane-less organelles and RNA binding proteins: The biological underpinnings of neurodegeneration, Dept. of Anatomy, BUSM, September, 2018.
32. Common Mechanisms of Neurodegeneration – RNA binding proteins, NIH Alzheimer's Research Summit: Path to Treatment and Prevention, Bethesda, MD, March 2017.
33. Membrane-less organelles and Neurodegeneration: The biological underpinnings of neurodegeneration, Duesseldorf-Juelich Symposium on Neurodegenerative Diseases, November, 2017.
34. Membrane-less organelles and Neurodegeneration: The biological underpinnings of neurodegeneration. Brain Aging and Dementia Control, Nagoya, Japan, September, 2017.
35. Membrane-less organelles and Neurodegeneration: The biological underpinnings of neurodegeneration. University of New Delhi, October, 2017
36. Membrane-less organelles and Neurodegeneration: The biological underpinnings of neurodegeneration. Dept. of Biochemistry, Emory University, October 2017

37. Environmental toxicants linked to ALS, NIEHS, Research Triangle Park, North Carolina, September, 2017

38. Stress granules and Neurodegeneration: A molecular network underlying neurodegeneration. Checkpoints and Quality Control, Turku, Finland, August, 2017

39. Stress granules and Neurodegeneration: A molecular network underlying neurodegeneration. University of South Hampton, South Hampton, England, July 2017

40. Tau-induced neurodegeneration is mediated by RNA binding proteins, Alzheimer Association International Conference (AAIC), London, England, July 2017 (Session chair)

41. Contributions of RNA Binding Proteins to tau biology and tauopathies. Phase Transitions in Biology and Disease, Leuven, Belgium, May 2017

42. Stress pathways contributing to the pathophysiology of tauopathies. Boston University School of Medicine, Department of Neurology, April, 2017

43. Reduction of the RNA binding protein TIA1 protects against tauopathy independent of tau aggregation. (Session Chair) ADPD 2017, Vienna, Austria, April 2017

44. What causes dementia and ALS? What can we do about it? Boston University School of Medicine, Gerontology Section, February, 2017

45. Stress granules and Neurodegeneration: A molecular network underlying neurodegeneration. Loyola University School of Medicine, January, 2017

46. The impact of RNA binding proteins on pathways of tau aggregation. DZNE, Bonn, Germany, December 2016

47. RNA binding proteins and the translational stress response: the Achilles heel for neurodegeneration.
    Kings College, London, England, December 2016

48. RNA Binding Proteins Interact with Tau to Modulate Pathology and Disease Progression, Drug Discovery and Therapy World Congress 2016, Boston, MA, August, 2016

49. Stress granules and Neurodegeneration: A molecular network underlying neurodegeneration. Jungers Symposium. Oregon Health Sciences University. Portland, OR May, 2016.

50. Stress granules and Neurodegeneration: A molecular network underlying neurodegeneration. University of Kentucky, Lexington, KY, October, 2015

51. Stress granules and Neurodegeneration: Novel targets for therapy in Amyotrophic lateral sclerosis and Alzheimer's disease. Drug Discovery & Therapy World Congress 2015. Boston, MA July, 2015

52. Interaction Between Microtubule Associated Protein Tau and RNA Binding Proteins Stimulates Tau Misfolding and Stress Granule Formation. Alzheimer's Association International Conference, 2015, Washington, DC, July 2015. Session chair.

53. Stress granules and Neurodegeneration: A molecular network underlying neurodegeneration and directing disease-modifying therapies. Keynote Speaker. NeuroConX, Prince Edwards Island, Canada, July, 2015. Public lecture, Business Talk and Scientific talk.

54. Aggregation of RNA Binding Proteins to form RNA granules: Biological substrates contributing to neurodegeneration. EMBO Workshop on Macromolecular Assemblies at the Crossroads of Cell Stress and Function, Israel Institute for Advanced Studies, Tel Aviv, Israel. June, 2015

55. RNA granules and Neurodegeneration: A molecular network underlying neurodegeneration. Dept. of Neurology, University of Massachusetts Medical School, May, 2015.

56. A novel therapeutic approach to ALS: Inhibition of TDP-43 aggregation and formation of TDP-43 positive pathological stress granules. ADPD2015, Nice, FR, April, 2015.

57. Stress granules and Neurodegeneration: A molecular network underlying neurodegeneration. Center for Systems Neuroscience, Boston University, February, 2015

58. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration. Southern Methodist University. October, 2014

59. Mechanism and Treatment of Tauopathies based on RNA binding proteins. CurePSP Meeting, Baltimore, MD, October 2014

60. Stress granules and Neurodegeneration: A new paradigm for mechanisms of neurodegeneration. World Congress on Geriatrics and Neurodegeneration. Corfu, Greece, April, 2014. Keynote speaker.

61. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration. The Stark Neurosciences Research Institute, Indianapolis, January 2014

62. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration. Nathan Kline Institute, Menands, NY, January 2014

63. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration. Thomas Jefferson University, Philadelphia, PA, Dec., 2013

64. Contributions of RNA binding Proteins to Alzheimer's disease, RNA metabolism in neurological disease, 8th Brain Research Conference, (SFN pre-meeting), San Diego, CA, November 2013

65. An Expanding Role for RNA Binding Proteins in Neurodegenerative Diseases: Alzheimer's and Parkinson's disease. University of Pennsylvania, Philadelphia, PA, October 2013

66. Future treatments for Parkinson's disease: Novel therapeutic approaches derived from a mechanistic understanding of disease. Clinical Neuroscience Grand Rounds, BUMC, Boston, MA, Sept. 2013

67. Viewing Neurodegeneration Beyond the Tangle: The role of RNA binding proteins in Alzheimer's disease. Alzheimer Association International Conference, Boston, MA, July 2013. Note: Session Chair

68. Stress Granules in Neurodegenerative Disease: A New Paradigm. Northwestern, Chicago, IL. April, 2013.

69. Mechanisms of LRRK2 Action: Cytoskeletal control of trafficking and autophagy, ADPD2013 meeting, Florence Italy, March, 2103. Note: Session Chair.

70. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration. Columbia University, New York, NY, January, 2013

71. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration Georgetown University, Washington, DC, January, 2013.

72. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration. Purdue University, West Lafayette, IN, October, 2012

73. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration, 11th International Symposium on Neurobiology and Neuroendocrinology of Aging, Bregenz, Austria, August, 2012.

74. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration. Conference: Neurons Under Stress 2012, Royal College of Surgeons Ireland, Dublin, Ireland, September, 2012.

75. The Biology of Parkinson's disease: Mechanisms and Therapeutic Targets. The Parkinson's Center, Darmouth-Hitchcock Lebanon, NH. October, 2012. Keynote speaker.

76. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration, Center for Neurologic Disease, Brigham and Women's Hospital, Harvard University, Boston, October 2012

77. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration, Mayo Clinic, Jacksonville, FL., May, 2012

78. Mechanisms of LRRK2 Action: From Networks to Protein Interactions. University of Tuebingen, Tuebingen, Germany December 2011.

79. Viewing Neurodegeneration Beyond the Tangle: Stress granules and Neurodegeneration, University of Homburg, Homburg, December, Germany, December 2011.

80. The Biology of Parkinson's Disease: Mechanisms and Therapeutic Targets. J. Stephen Fink M.D., Ph.D. Memorial Lecture. Boston University School of Medicine, Boston, MA, December 2011

81. Stress Granules and Neurologic Disease. Mini-symposium presentation. Society for Neuroscience, Washington, DC, November, 2011. Symposium organizer.

82. LRRK2: Regulating autophagy and mitochondrial dynamics in Parkinson disease. University of Alabama, Birmingham, AL, September, 2011.

83. Stress Granules and Alzheimer's disease: Co-localization with Tau Pathology. International Conference on Alzheimer's disease, Paris, France. July 2011. Session Chair.

84. A functional regulatory network for LRRK2. Karolinska Institute, Stockholm, Sweden, May 2011.

85. LRRK2: Integrating the stress response in Parkinson disease. American Society for Neurochemistry, St. Louis, MO, March, 2011.

86. Regulation of Physiologic Actions of LRRK2. ADPD 2011, Barcelona, Spain, March, 2011. Session Chair

87. Stress Granules and Neurodegenerative Disease—What's the Scoop? Alzforum.org Webinar, February, 2011.

88. The Brain – Heart Health Connection, General Lecture, Rhode Island Alzheimer Association, Providence, RI, Nov, 2010.

89. C.elegans models of Alzheimer's disease and Parkinson's disease: Systems Biology Identifies LRRK2 shared interaction networks. ICAD 2010, Honolulu, Hawaii, July 2010.

90. Assessing the Impact of Therapies for Cardiovascular Disease on Dementia. Hebrew Senior Life Center, Boston, MA, June 2010.

91. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: a prospective cohort analysis. Novartis. Boston, MA, June 2010.

92. The Role of Cholesterol in Alzheimer's disease. University of North Dakota, May 2010.

93. Mechanism of Protein Aggregation in Neurodegenerative Diseases. Alzheimer's disease Center, Boston University School of Medicine, April 2010.

94. Convergent Pathways in Parkinson's disease: Implications for Therapy. Grand Rounds. Dept. of Neurology, Boston University School of Medicine. Jan 2010.

95. LRRK2: Regulating the Stress Response and Unraveling Protein Aggregation. World Brain Conference. Orlando, FL, Dec 2009.

96. LRRK2 and the Stress Response. Plenary Presentation. Korean Society for Molecular Biology and Biochemistry. Seoul, South Korea, October 2009.

97. LRRK2 and the Stress Response: Investigating Molecular Networks in Parkinson's Disease. Seoul National University College of Medicine, Seoul, South Korea, October, 2009.

98. Role of statins in prevention and treatment of Alzheimer's disease. Kupio Alzheimer Symposium. Kuopio, Finland, June, 2009.

99. LRRK2: Role in the stress response and control of neurite function. Harvard Institutes for Medicine, April, 2009.

100. LRRK2 and the Stress Response, 9th International Conference on Alzheimer's and Parkinson's disease, Prague, Czechoslovakia, March, 2009

101. Stress Granules and Neurodegeneration: A novel paradigm for understanding inclusion formation, Boston University School of Medicine, Dec, 2008

102. Peering into the biology of Parkinson's disease: genes, dopamine and degeneration. Wesleyan, University, June, 2008

103. Peering into the biology of Parkinson's disease: genes, dopamine and degeneration. Albany Medical College, Albany, May, 2008

104. Pharmacoepidemiology: Identifying neuroprotective strategies for Alzheimer's disease. University of Tennessee, April, 2008.

105. Update on Parkinson's disease. Grand Rounds, Dept. of Neurology, Boston University School of Medicine, January, 2008.

106. Managing Misfolded Proteins: LRRK2 and Parkinson's disease. Genetics and Genomics, Boston University School of Medicine, October, 2007.

107. Update on Parkinson's disease. Grand Rounds, Dept. of Medicine, Boston University School of Medicine, Sept., 2007.

108. Peering into the biology of Parkinson's disease: Genes, Protein aggregation and oxidative injury. University of Buffalo, Sept., 2007

109. Peering into the biology of Parkinson's disease: Aggregation, oxidation and injury. Northeastern University, Boston, MA. April, 2007

110. Neuroprotective strategies for Alzheimer's and Parkinson's disease. Taub Institute, Columbia University, College of Physicians and Surgeons, New York, NY. February, 2007.

111. Parkinson's disease: Biology beyond dopamine. Dept. of Neurology, Boston University School of Medicine. November, 2006.

112. Parkinson's disease: Biology beyond dopamine. Dept. of Pathology, University of Pennsylvania School of Medicine. October, 2006

113. Comprehensive Analysis of the Effects of Medications on Alzheimer disease. International Conference on Alzheimer disease. Madrid, Spain. July, 2006.

114. Genes, aging and the environment: Convergent pathways in Parkinson disease. Medical University of South Carolina. Charleston, SC. June 2006.

115. Convergent Pathways in Parkinson's disease. Dept. Genetics, Boston University School of Medicine. March 2006.

116. Interaction of disease associated proteins with mitochondria and the proteasome in Parkinson's disease. World PD Meeting, Washington DC, Feb, 2006.

MEETINGS ORGANIZED:

1. Boston University Parkinson's disease forum, Sept. 30, 2005
2. Boston University Parkinson's disease forum, June 15, 2007
3. Boston University Parkinson's disease forum, Feb. 12, 2009

4. Boston University Parkinson's disease forum, April, 2015

PUBLICATIONS (Professional)

1. **Wolozin, B.L**.: Towards an understanding of beta-lactamase catalysis. Undergraduate Thesis, 1980.

2. **Wolozin, B.L**., and Pasternak, G.W.: Classification of multiple morphine and enkephalin binding sites in the central nervous system. PNAS 78(10):6181-6185, 1981.

3. **Wolozin, B.L**., Nishimura, S., and Pasternak, G.W.: The binding of Kappa and Sigma Opiates in rat brain. J. Neuroscience 2(6): 708-713, 1982.

4. **Wolozin, B.L**., Myerowitz, R., and Pratt, R.F.: Specific chemical modification of the readily nitrated tyrosine of the RTEM beta-lactamase and of bacillus cereus beta-lactamise I. The role of tyrosine in beta-lactamase catalysis. Biochem. Biophysics Acta 701(2):153-163, 1982.

5. **Wolozin, B.L**., Pruchnicki, A., Dickson, D.W., and Davies, P.: A neuronal antigen in the brains of Alzheimer patients. Science 232:648-650, 1986. PMID 3083509

6. **Wolozin, B.L**., and Davies, P.: Recent advances in the neurochemistry of Alzheimer's Disease. J. Clin. Psychiatry. 48:23-30, 1987.

7. **Wolozin, B.L**., and Davies, P.: Alzheimer related neuronal protein A68: specificity and distribution. Ann. Neurol. 22:521-526, 1987.

8. Davies, P., Scicutella, A., and **Wolozin, B.L**.: A new protein in Alzheimer's Disease. Branberry Reports 27:459-471, 1987.

9. **Wolozin, B.L**.: A neuronal antigen in the brains of Alzheimer patients. Graduate Dissertation, 1987.

10. **Wolozin, B.L.,** Scicutella, A., and Davies, P.: Re-expression of a developmentally regulated antigen in Down Syndrome and Alzheimer's Disease. PNAS 85:6202-6206, 1988.

11. Hyman, B.T., Van Hoesen, G.W., **Wolozin, B.L**., Davies, P., and Damasio, A.R.: Alz-50 antibody recognizes Alzheimer-related neuronal changes. Ann. Neurol. 27:371-379, 1988.

12. **Wolozin, B.L**.: Immunochemical approaches to the diagnosis of Alzheimer's Disease. In: Becker, R.E., and Giacobini, E. (Eds.) Alzheimer's Disease. Current Research in Early Diagnosis, Taylor and Francis, New York: 1990; 217-235.

13. Lesch, K.P., Aulakh, C.S., Tolliver, T.J., Hill, J.L., **Wolozin, B.L**., and Murphy, D.L.: Differential effects of long-term lithium and carbamazepine administration on $G_{s\_}$ and $G_{i\_}$ protein in rat brain. Eur. J. Pharmacol. 207:355-359, 1991.

14. **Wolozin, B.L**., Sunderland, T., Zheng, B.B., Resau, J., Dufy, B., Barker, J., Swerdlow, R.D., and Coon, H.: Continuous culture of neuroblasts from adult human olfactory epithelium. J. Mol. Neuroscience 3:137-146, 1992.

15. **Wolozin, B.L**., Bacic, M., Merrill, M.J., Lesch, K.P., Chen, C., Lebovics, R.S., and Sunderland, T.: Differential expression of carboxyl terminal derivatives of amyloid precursor protein among cell lines. J. Neurosci. Res. 33:163-169, 1992

16. **Wolozin, B.L**., Chung, D., Zheng, B.B., Lesch, K.P., Lebovics, R.S., and Sunderland, T.: The β/A4 domain of APP: Antigenic differences between cell lines. J. Neurosci. Res. 33:189-197, 1992.

17. Lesch, K.P., Hough, C.J., Aulakh, C.S., **Wolozin, B.L**., Tolliver, T.J., Hill, J.L., Chuang,D.M., and Murphy, D.L.: Fluoxetine modulated G protein s_s , q_q and α_{12} subunit mRNA expressed in rat brain. Eur. J. Pharmacol. 227:233-237, 1992.

18. Lesch, K.P., Aulakh, C.S., **Wolozin, B.L**., Tolliver, T.J., Hill, J.L., and Murphy, D.L.: 3-(2-Carboxypiperazin-4-yl)Propyl-1-phosphonic acid decreases NMDA receptor mRNA. Eur. J. Pharmacol. 227:109-111, 1992.

19. Lesch, K.P., Aulakh, C.S., **Wolozin, B.L**., and Murphy, D.L.: Serotonin (5-HT) receptor, 5-HT transporter and protein-effector expression: Implications for depression. Pharmacol. Toxicol. 71:49-60, 1992.

20. Lesch, K.P., Aulakh, C.S., **Wolozin, B.L**., Tolliver, T.J., Hill, J.L., and Murphy, D.L.: Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Mol. Brain Res. 17:31-35, 1993.

21. **Wolozin, B.L**., Lesch, K.P., Lebovics, R.S., and Sunderland, T.: Olfactory neuroblasts from Alzheimer donors: Studies on APP processing and cell regulation. Biol. Psychiatry. 34:824-838, 1993.

22. Lesch, K.P., **Wolozin, B.L**., Estler, H.C., Murphy, D.L., and Riederer, P.: Isolation of a cDNA encoding the human brain serotonin transporter. J. Neural Transm. 91: 67-72, 1993.

23. Lesch, K.P., Aulakh, C.S., **Wolozin, B.L**., Riederer, P., Hill, J.L., and Murphy, D.L.: Norepinephrine, serotonin and vesicular monoamine transporter in depression and bipolar disorder: Expression during long-term antidepressant treatment. Neuropsychopharmacology 9:34S-35S, 1993.

24. **Wolozin, B.L**.: The processing of amyloid precursor protein. Foundation Ipsen: Alzheimer Actualities 7:6-8, 1993.

25. Lesch, K.P., Gross, J., **Wolozin, B.L**., Murphy, D.L., and Riederer, P.: Extensive sequence divergence between the human and rat brain vesicular monoamine transporter: Possible molecular basis for species differences in the susceptibility to MPP^+. J. Neural Transm. 93:75-82, 1993.

26. Lesch, K.P., **Wolozin, B.L**., Murphy, D.L., and Reiderer, P.: Primary structure of the human platelet serotonin uptake site: Identity with the brain serotonin transporter. J. Neurochem. 60:2319-2322, 1993.

27. Johnson, G., Brane, D., Basaric-Keys, J., Lebovics, R.S., Merril, C.R., Sunderland, T., and **Wolozin, B.L**.: Protein alterations in olfactory neuroblasts from Alzheimer donors. Neurobiol. Aging 15:675-680, 1994.

28. Lesch, K.-P., Balling, U., Gross, J., Strauss, K., **Wolozin, B.L**., Murphy, D.L., and Riederer, P.: Organization of the human serotonin transporter gene. J. Neural Transm. 95: 157-162, 1994.

29. Lesch, K.P., Gross, J., **Wolozin, B.L**., Franzek, E., Riederer, P., Murphy, D.L., Direct Sequencing of the reserpine-sensitive vesicular monoamine transporter complementary DNA in unipolar depression and manic-depressive illness. Psychiatric Genetics 4: 153-90 (1994).

30. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, L., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, Hua., Vitale, J., Wadsworth, S., **Wolozin**, **B.**, and Zhao, J.: Development of neuropathology similar to Alzheimer's Disease in transgenic mice overexpressing the $717_{V\text{-}F}$ β-amyloid precursor protein. Nature, 373: 523-8, 1995.

31. Luo, Y Q. , Hirashima, N., Li, Y.H., Alkon, D.L., Sunderland, T., Etcheberrigaray, R., and **Wolozin, B.L**.: Physiological levels of β-amyloid increase tyrosine phosphorylation and cytosolic calcium. Brain Res., 681: 65-74 (1995).

32. **Wolozin,B**., Hirashima, N., Luo, Y.,Li, Y.H., Alkon, D.L., Etcheberrigaray, R. and Sunderland, T., Transforming growth factor induces a responsive calcium fluxes in neurons. NeuroReport, 6: 1301-5 (1995).

33. Lesch, K.P., Franzek, E., Gross, J., **Wolozin, B.L**., Riederer, P., and Murphy, D.L.: Primary Structure of the Serotonin transporter in unipolar and bipolar disorder. Biol. Psychiatry. 37: 215-23 (1995).

34. Iwasaki, K., Sunderland, T., Kusiak, J.W. and **Wolozin, B**., Changes in gene transcription during a_-mediated cell death. Mol. Psych. 1: 65-71 (1996).

35. **Wolozin, B.**, Luo, Y., and Wood, K.: Neuronal Loss and Aging in Cellular Aging and Cell Death, Eds. N.J. Holbrook, G.R. Martin and R. A. Lockshin (John Wiley & Sons, Inc., NY) 283-302 (1996).

36. **Wolozin, B.L**., Basaric-Keys, J., Canter, R., VanderPutten, D., and Sunderland, T.: Differential regulation of APP by apolipoprotein E3 and E4. Ann. NY Acad. Sci. 777:322-6 (1996).

37. **Wolozin, B**., Basaric-Keys, J., Canter, R., Li, Y., Strickland, D and Sunderland, T., Differential regulation of APP secretion by apolipoprotein E3 and E4, Neurodegenerative Diseases '95: Molecular and Cellular Mechanisms. Ed. G. Fiskum (Plenum, Press, NY) 97-102 (1995).

38. Luo, Y., Sunderland, T. and **Wolozin, B**., Physiologic Levels of β-Amyloid Activate PI3-Kinase with the Involvement of Tyrosine Phosphorylation. J. Neurochem. 67:978-987 (1996).

39. Vawter, M.P., Basaric-Keys, J., Li, Y., Lebovics, R.S., Lesch, K.P., Kulaga, H., Freed, W.J., Sunderland, T., **Wolozin, B**., Human olfactory neuroepithelial cells: Tyrosine phosphorylation and process extension are increased by the combination of IL1_, IL6, NGF and βFGF. Exp. Neurol.. 142:179-194, 1996.

40. Vito, P., **Wolozin, B**, Ganji, K, Iwasaki, K., Lacana, E. and D'Adamio, L. Requirement of the familial Alzheimer's Disease gene PS-2 for apoptosis. J. Biol. Chem. 271:31025-31028, 1996.

41. **Wolozin, B**., Iwasaki, K, Vito, P., Sunderland, T., Ganji, K., Lacana, E., Zhao, B., Kusiak, J., Wasco, W. and D'Adamio, L. Participation of Presenilin-2 in apoptosis: Enhanced basal activity conferred by Alzheimer mutation. Science. 274:1710-1713, 1996.

42. **Wolozin, B.** Redoubling our effort in redox chemistry. Mol. Psych. 1:352-355, 1996.

43. Luo, Y., Sunderland, T., Roth, G.S. and **Wolozin, B**. Physiological levels of _-amyloid peptide promote PC12 cell proliferation. Neurosci. Lett. 217:125-128, 1996.

44. **Wolozin, B**. ICE and apoptosis. Mol. Psych. 2:184-187, 1997.

45. Goldstein, B.J., **Wolozin, B.L**., Schwob, J.E. FGF2 supresses neuronogenesis of a cell line derived from rat olfactory epithelium. J. Neurobiol. 33:411-8, 1997.

46. Luo, Y., Hawver, D. B., Iwasaki, K., Sunderland, T., Roth, G. S. and **Wolozin, B**. Physiological levels of ß-amyloid peptide stimulate protein kinase C in PC12 cells. Brain Res. 769:287-95, 1997.

47. Wallace., W, Akar, C., Lyons, W.E., Kole, W.E., Egan, J., **Wolozin, B**., Amyloid precursor protein requires the insulin signaling pathway for neurotrophic activity. Molecular Brain Research 52: 213-227, 1997.

48. **Wolozin, B**., Alexander, P., Palacino, J. Regulation of apoptosis by presenilins. Neurobiol. Aging. 19 (1S): S23-7, 1998.

49. Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Yamaguchi, H., Sugihara, S., **Wolozin, B**. Presenilin 1 Associates with Glycogen Synthase Kinase-3β, Proc. Natl. Acad. Sci., USA. 95: 9637-41, 1998.

50. Murayama M; Tanaka S; Palacino J; Murayama O; Honda T; Sun X; Yasutake K; Nihonmatsu N; **Wolozin B**; Takashima A. Direct association of presenilin-1 with beta-catenin. FEBS Lett 14: 433:73-7, 1998.

51. **Wolozin, B**., Jones, C., Maheshwari, S., Dukoff, R., Nagula, S., Shulman, N.R. and Sunderland, T., Physiologic levels of ß-amyloid augment platelet aggregation: Reduced activity of familial angiopathy-assoicated mutants. Mol. Psych. 3: 500-507, 1998

52. **Wolozin, B**. and Palacino, J., Presenilins and their role in apoptosis. In eds. C. Haass, The Molecular Biology of Alzheimer's Disease. Harwood Academic Publishers, Australia. 1998. pp. 247-76

53. Abrams, MT, Kaufmann, WE, Rousseau, F, Oostra, BA, **Wolozin, B**, Taylor, CV, Lishaa, N, Morel, ML, Hoogenveen, A, Reiss, AL. FMR1 gene expression in olfactory neuroblasts from two males with fragile X syndrome. Am. J. Med. Gen. 82: 25-30, 1999.

54. **Wolozin, B**. Genes in Alzheimer's Disease, in "Genes, Behaviour and Health", (Advisory Committee on Health Research of the World Health Organization, Geneva, Switzerland). pp. 123-144, 1999.

55. Ostrerova, N., Petrucelli, L., Farrer, M., Mehta, N., Palacino, J., Hardy, J. and **Wolozin, B.** _-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19: 5782-91, 1999.

56. Sunderland T; **Wolozin B**; Galasko, D., Levy, J., Dukoff, R., Bahro, M., Lasser, R., Motter, R., Lehtimaki, T., Seubert, P., Longitudinal stability of CSF tau levels in Alzheimer patients. Biol. Psych. 46:750-5, 1999.

57. Palacino, J., Berechid, B., C. Eckman, S. Younkin, Alexander, P., Nye, J., **Wolozin, B**. Regulation of APP processing by Presenilin 1 and 2 in Presenilin 1 knockout cells. J. Biol. Chem. 275: 215-222, 2000.

58. **Wolozin, B**. and Behl, C., Mechanisms of neurodegenerative disorders. Part A: Protein Aggregates. Arch. Neurol. 57: 793-6, 2000

59. **Wolozin, B**. and Behl, C., Mechanisms of neurodegenerative disorders. Part B: Control of cell death. Arch. Neurol. 57: 797-800, 2000

60. Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J.M., Farer, M., **Wolozin, B**., The A53T α-Synuclein Mutation Increases Iron-Dependent Aggregation and Toxicity. J. Neurosci. 20: 6048-54, 2000.

61. Choi, P., Ostrerova-Golts, N., Sparkman, D., Cochran, E., Lee, J.M., **Wolozin, B**., Parkin is Metabolized by the Ubiquitin/Proteosome System, NeuroReport 11: 2635 – 9, 2000.

62. ***Wolozin, B.L.**, Kellman, W., Ruosseau, P., Celesia, G.G. and Siegel, G., Decreased Prevalence of Alzheimer's Disease, Associated with HMG-CoA Reductase Inhibitors. Archives Neurol., 57: 1439 – 1443, 2000. *Reviewed in the Editors Choice column of Science, 290: 1857 (2000), and discussed in Science, 294: 506-7 (2001) PMID 11030795.

63. **Wolozin, B.,** A fluid connection: Cholesterol and Aβ, (Invited Commentary) PNAS 98:5371-3 (2001).

64. **Wolozin, B.**, Peering into proteolylsis with presenilins, (Invited Commentary) Journal Alz. Dis. 3: 191-3 (2001).

65. **Wolozin, B**., Golts, N., Choi, P., Frasier, M., Snyder, H. and Palacino, J., Looking beyond β-amyloid: α-Synuclein and Neurodegeneration. Research and Practice in Alzheimer's

disease, Vol. 4, 2001.

66. Choi, P., Golts, N., Snyder, H., Petrucelli, L., Chong, M., Hardy, J.,Sparkman, D., Cochran, E., Lee, J.M., **Wolozin, B.,** Co-association of parkin and α-synuclein, NeuroReport. 12: 2839-45 (2001).

67. Palacino, J.J., Murphy, M.P., Murayama, O., Iwasaki, K., Fujiwara, M., Takashima, A., Golde, T.E., **Wolozin, B**., Presenilin 1 Regulates β-Catenin-Mediated Transcription in a GSK 3β-Independent Fashion JBC 276(42):38563-38569 (2001).

68. Ahn, B. H., Rhim, H., Kim, S. Y., Sung, Y. M., Lee, M. Y., Choi, J. Y., **Wolozin, B**., Chang, J. S., Lee, Y. H., Kwon, T. K., Chung, K. C., Yoon, S. H., Hahn, S. J., Kim, M. S., Jo, Y. H., and Min, D. S. Alpha-synuclein interacts with phospholipase D isozymes and inhibits pervanadate induced phospholipase D activation in human embryonic kidney 293 cells. J Biol Chem. 277(14):12334-42 (2002).

69. **Wolozin, B.** and Siegel, G., Response to letter: Statins and Dementia. Archives Neurol. 58: 1169 (2001).

70. **Wolozin, B.** and Siegel, G., Response to Letter: Statin-Alzheimer Disease Association Not Yet Proven. Archives Neurol. 58: 1022 (2001).

71. **Wolozin, B.** and Siegel, G., Response to Letter: Statin Therapy and the Prevention of Dementia. Archives Neurol. 58: 1023 (2001)

72. **Wolozin, B**. and Golts, N., Synuclein, iron and Parkinson's disease, The Neuroscientist. 8(1): 22-32 (2002).

73. Golts, N., Snyder, H., Frasier, M., Theisler, C., Choi, P., **Wolozin, B**. Magnesium inhibits spontaneous and iron-induced aggregation of alpha –synuclein. J. Biol. Chem. 277:16116-23 (2002).

74. **Wolozin, B.**, Cholesterol and Alzheimer's disease. Biochemical Society Transactions 30(4): 525-30 (2002).

75. Petrucelli, L., O'Farrell, C., Kehoe, K., Vink, L., Lockhart, P.J., Baptista, M., Choi, P., **Wolozin, B**., Farrer, M., Hardy, J., Cookson, M.R., Parkin protects against the toxicity associated with over-expression of synuclein: Proteasome dysfunction selectively affects dopaminergic neurons. Neuron 36:1007-19 (2002).

76. Egashira N, Iwasaki K, Ishibashi M, Hatip-Al-Khatib I, **Wolozin B**, Mishima K, Irie K and Fujiwara M., Hypoxia Enhances beta-Amyloid-Induced Apoptosis in Rat Cultured Hippocampal Neurons. Japanese J Pharmacol 90:321-327 (2002).

77. **Wolozin, B.**, Cyp46 (24-Cholesterol Hydroxylase): A genetic risk factor for Alzheimer's Disease. Archives of Neurology 60:16-8 (2003) (invited commentary).

78. Snyder, H., Mensah, K., Theisler, C., Lee, J. M., Matouschek, A. and **Wolozin, B.**, Aggregated and Monomeric α-Synuclein bind to the S6' Proteasomal Protein and Inhibit Proteasomal Function. J. Biol. Chem. 278:11753-9 2003.

79. Choi P., Snyder, H. ,Petrucelli L., Theisler, C., Chong M., Zhang Y., Lim K. , Chung K. , Kehoe K. , L. D'Adamio, Lee J.M., Cochran E., Bowser R., Dawson T., **Wolozin, B**., SEPT5 v2 is a parkin-binding protein. Mol. Brain Res. 117:179-189 (2003).

80. Perry G, Castellani RJ, Smith MA, Harris PL, Kubat Z, Ghanbari K, Jones PK, Cordone G, Tabaton M, **Wolozin B**, Ghanbari H., Oxidative damage in the olfactory system in Alzheimer's disease. Acta Neuropathol (Berl). 106:552-6 (2003).

81. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, Girones X, Henry TL, Matsubara E, Zambon D, **Wolozin B**, Sano M, Cruz-Sanchez FF, Thal LJ, Petanceska SS, Refolo LM. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology.61:199-205 (2003).

82. **Wolozin, B**. Cholesterol and the Biology of Alzheimer's disease. Neuron 41:7010 (2004) (Invited Commentary).

83. Petrucelli, L., Dickson, D., Kehoe, K., Taylor, J., Snyder, H., Grover, A., McGowan, E., Lewis, J., Dillman, W., Browne, S.E., Voellmey, R., Tsuboi, Y., Dawson., T.M., **Wolozin, B**., Hardy, J., Hutton, M., CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Human Molecular Genetics 13:703-14 (2004).

84. Frasier, M., **Wolozin, B.**, Following the leader: Fibrillization of α-synuclein and tau. Exp. Neurol. 187:235-9 (2004) (Invited Commentary).

85. **Wolozin, B.**, Apo E Receptor LR11: Intersections between Neurodegeneration and Cholesterol Metabolism. Arch. Neurol. 61:1178-80 (2004) (Invited commentary).

86. **Wolozin, B.**, Brown, J., Theisler, C., Silberman, S., The Cellular Biochemistry of Cholesterol and Statins: Insights into the Pathophysiology and Therapy of Alzheimer's Disease. CNS Drug Reviews 10:127-46 (2004).

87. Ghanbari HA, Ghanbari K, Harris PL, Jones PK, Kubat Z, Castellani RJ, **Wolozin BL**, Smith MA, Perry G., Oxidative damage in cultured human olfactory neurons from Alzheimer's disease patients. Aging Cell. 3:41-4 (2004).

88. Brown, J., Theisler, C., Silberman, S., Magnuson, D., Russell, D.W., Marquez-Sterling, N., Lee, J.M., Yager, D., Crowley, J., Sambamurti, K., Rahman, M., Reiss, A.B., Eckman, C.B., **Wolozin, B**., Differential Expression of Cholesterol Hydroxylases in Alzheimer's disease. JBC 279:34674-81 (2004).

89. Frasier, M., Walzer, M., McCarthy, L., Magnuson, D., Lee, J.M., Haas, C., Kahle, P. and **Wolozin, B**., Tau phosphorylation increases in symptomatic mice over-expressing A30P α-synuclein. Exp. Neurol, 192:274-87 (2005).

90. Poon, H.F., Frasier, M., Kahle, P., Haass, C., Sherve, N., Calabrese, V., **Wolozin, B.,** Butterfield, D.A. Mitochondrial associated Metabolic Proteins are Selectively Oxidized in A30P α-Synuclein Transgenic Mice – A Model of Familial Parkinson's Disease. Neurobio. Dis., 18:492-8 (2005).

91. Snyder, H., Mensah, K., Hashimoto, M., Surgucheva, I.G., Festoff, B., Surguchov, A., Masliah, E., Matouschek, A., **Wolozin, B**. β-Synuclein Reduces Proteasomal Inhibition by α-Synuclein but not γ-Synuclein. JBC 280:7562-9 (2005).

92. Snyder, H., **Wolozin, B**., Pathological proteins in Parkinson's disease: focus on the proteasome. J Mol Neurosci. 24:425-42 (2005).

93. Lee, TA **Wolozin*, B**, Weiss, K, Bednar, MM, Assessment of the Emergence of Alzheimer's Disease Following Coronary Artery Bypass Graft Surgery or Percutaneous Transluminal Coronary Angioplasty. J. Alzheimer's Disease 7:319-24 (2005) (*Corresponding Author).

94. Ved, R., Saha, S., Sluder, A., Westlund, B., Burnam, L., Hoener, M., Przedborsky, S., Alfonso, A., Liu, L., **Wolozin, B**. Similar Patterns of Mitochondrial Vulnerability and Rescue Induced by Genetic Modification of α-Synuclein, Parkin and DJ-1 in *C. Elegans*. JBC, 280(52):42655-68 (2005).

95. **Wolozin, B.**, J. Manger, R. Bryant, J. Cordy, R.C.Green and A. McKee. Cholesterol, Alzheimer's disease and Statins: Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neuropathologica Suppl. 185:63-70 (2006).

96. Frasier, M., Frausto, S., Lewicki, D., Golbe, L., **Wolozin, B.,** DJ-1 Expression Increases in Mice Over-Expressing A30P α-Synuclein. In ALZHEIMER'S AND PARKINSON'S DISEASES: INSIGHTS,PROGRESS AND PERSPECTIVES (Eds., Hanin and Fisher, Springer, NY) (2008).

97. Wolozin, H and **Wolozin, B**., The Unconscious in Economic Decision-Making: Convergent Voices. Journal of Socio-Economics (2006).

98. **Wolozin, B**., Interpreting Clinical Studies of Putative Therapeutics for Alzheimer's disease. In, ed. Cuello, C., Pharmacological and Mechanisms in Alzheimer's Therapeutics (Springer, NY, 2006).

99. **Wolozin, B**. and Bednar, M. M., Interventions for Heart Disease and Their Effects on Alzheimer's disease, In, ed., de la Torre, J. C., Impact of Heart Disease and Stroke on Alzheimer's Disease, Neurologic Research 28:630 – 6 (2006).

100. **Wolozin, B**., Cholesterol, Statins and Alzheimer's disease: Past, Present and Future, In, ed. Sun, M. K., Research Progress in Alzheimer's Disease and Dementia (2006).

101. Takashima A, Shimojo M, **Wolozin B**. The players on the gamma-secretase team. Nat Med. Jul;12(7):766-767 (2006).

102. Bednar M.M., Lee TA, Wolozin B, Weiss K.B.. Coronary artery bypass grafting is not a risk factor for dementia or Alzheimer disease. Neurology. Jun 13;66(11):1785 (2006).

103. Cordy, J.M. and Wolozin, B, Cholesterol and Alzheimer's disease. In eds Barrow C.J., Small D.H.. Abeta Peptide and Alzheimer's Disease: Celebrating a Century of Research. (London: Springer-Verlag, 2006, 312 pp).

104. **Wolozin, B**., Wang, SW, Lee, A, Lee TA, Kazis, LE, Use of simvastatin is associated with a reduction in the incidence of dementia and Parkinson's disease. BMC Medicine 5:20 (2007). PMID: 17640385

105. **Wolozin, B**., Saha, S., Guillily, M., Ferree, A., Riley, M., Investigating Convergent Actions of Genes Linked to Familial Parkinson's Disease. Neurodegenerative Diseases, 5:182-5 (2008). PMID: 18322385

106. Zerbinatti, CV, Cordy, JM, Chen, CD, Guillily, M, Suon, S, Ray, WJ, Seabrook, GR, Abraham, CR, **Wolozin, B**, Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein. Mol. Neurodegen 3:5 (2008). PMID: 18348724

107. Tezapsidis N, Johnston JM, Smith MA, Ashford JW, Casadesus G, Robakis NK, **Wolozin B**, Perry G, Zhu X, Greco SJ, Sarkar S., Leptin: a novel therapeutic strategy for Alzheimer's disease. J. Alz. Dis. 29:731-40 (2009). PMID: 19387109

108. Solomon A., Kåreholt I, Ngandu T, **Wolozin B**, Macdonald SW, Winblad B, Nissinen A, Tuomilehto J, Soininen H, Kivipelto M. Serum total cholesterol, statins and cognition in non-demented elderly. Neurobiol Aging. 30: 1006-9 (2009).

109. Saha, S., Guililly, M., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Segal, L., Raghavan, K., Hsu, C., Cordy, J., Kuwahara, T., Iwatsubo, T., Goldstein, L., Cookson, MR, and **Wolozin, B.,** LRRK2 modulates vulnerability to mitochondrial dysfunction in C. elegans J. Neurosci, 29:9210-8 (2009). PMID: 19625511

110. Solomon A, Kivipelto M, **Wolozin B,** Zhou J, Whitmer RA., Midlife Serum Cholesterol and Increased Risk of Alzheimer's and Vascular Dementia Three Decades Later. Dementia Geriatric Cogn. Disord. 28:75-80 (2009). PMID: 19648749

111. Hsu, CH, Chan, D, Greggio, E., Saha, S., Guillily, M.D., Ferree, A., Raghavan, K., Shen, GC, Segal, L., Ryu, H., Cookson, M. R., **Wolozin, B.**, MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J. Neurochem. 112(6): 1593-604 (2010). PMID: 20067578

112. Hsu, CH, Chan, D. and **Wolozin**, **B.**, LRRK2 and the stress response: Interaction with MKK and JNK interacting proteins, Neurodegen. Dis. 7(1-3):68-75 (2010). PMID: 20173330

113. *Li, N.C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L.E. and **Wolozin, B.,** Use of Angiotensin Receptor Blockers and the Risk of Dementia in a Predominantly Male Population: A Prospective Cohort Analysis**.** BMJ 340:b5465 doi: 10.1136/bmj.b5465 (2010). PMID: 20068258 * Commentary on the manuscript in the same issue of BMJ.

114. Liu-Yesucevitz, L., Bilgutay, A., Zhang, Y-Z., Mehta, T., Citro, A., Zaruur, N., McKee, A., Bowser, R., Sherman, M., Petrucelli, L. and **Wolozin, B**., Tar DNA Binding Protein-43 (TDP-43) Associates with Stress Granules: Analysis of Cultured Cells and Pathological Brain Tissue. Plos ONE (5(10). pii: e13250*)*, (2010) PMID: 20948999.

115. Kumar, A., Greggio, E., Beilina, A., Kaganovich, A., Chan, D., Taymans, J.M., **Wolozin, B**., Cookson, M.R., The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. Plos ONE 15(1):E8730 (2010). PMID: 20090955

116. Carballo-Carbajal, I., Weber-Endress, S.U.K., Klein, C., Patenge, N., Rovelli, G., **Wolozin, B**., Gasser, T. and Kahle P.J., Leucine-rich repeat kinase 2 induces α-synuclein expression via the extracellular signal regulated kinase pathway. Cell Signaling 22(5):821-7 (2010). PMID: 20074637

117. Solomon A, Sippola R, Soininen H, **Wolozin B**, Tuomilehto J, Laatikainen T, Kivipelto M., Lipid-lowering treatment is related to decreased risk of dementia: a population-based study (FINRISK), 7(1-3):180-2 (2010). PMID: 20224281

118. Vanderweyde T, Bednar MM, Forman SA and **Wolozin** B, Iatrogenic risk factors for Alzheimer's disease: Surgery and Anesthesia. Journal of Alzheimer's Disease. (2010) *Epub*. PMID: 20858967

119. **Wolozin, B.,** Lee, A., Li, N.C., Kazis, L.E., Pharmaco-epidemiological Studies Using the Veterans Affairs Health System Decision Support System Database, in Efficient Decision Support Systems: Practice and Challenges – From Current to Future / Book 3 (2011)(ISBN 978-953-308-63-9). Intechweb.org

120. Chan, D., Citro, A., Cordy, J.M., Shen, G.C., **Wolozin, B.**, Rac1 Rescues Neurite Retraction Caused By G2019s Leucine-Rich Repeat Kinase 2 (Lrrk2), J. Biol. Chem. 286(18):16140-9 (2011). PMID: 21454543.

121. **Wolozin B**, Gabel C, Ferree A, Guillily M, Ebata A., Watching worms whither: modeling neurodegeneration in C. elegans, Prog Mol Biol Transl Sci. 2011;100:499-514, PMID: 21377635.

122. Devine MJ, Kaganovich A, Ryten M, Mamais A, Trabzuni D, Manzoni C, McGoldrick P, Chan D, Dillman A, Zerle J, Horan S, Taanman JW, Hardy J, Marti-Masso JF, Healey D, Schapira AH, **Wolozin B**, Bandopadhyay R, Cookson MR, van der Brug MP, Lewis PA., Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue. PLoS One. 2011;6(7):e22489. Epub 2011 Jul 22. PMID: 21799870.

123. Liu-Yesucevitz, L., Bassell, G.J., Gitler, A.D., Hart, A.C., Klann, E., Richter, J.D., Warren, S.T. and **Wolozin, B**., Local RNA Translation at the Synapse and in Disease. J. Neurosci. 31:16086-93 (2011). PMID 22072660.

124. Ferree, A., Guillily, M., Li, H., Smith, K., Takashima, A., Squillace, R., Weigele, M., Collins, J.J., **Wolozin, B**., Regulation of the Physiologic Actions of LRRK2: Focus on Autophagy. Neurodegen. Dis., 10:238-41 (2012). PMID: 22204929

125. Vanderweyde, T., Yu, H., Varnum, M., Liu-Yesucevitz, L., Citro, A., Ikezu, T., Duff, K., **Wolozin, B.,** Contrasting Pathology of Stress Granule Proteins TIA-1 and G3BP in Tauopathies. J. Neurosci. 32:8270-83 (2012). PMID: 22699908.

126. Liu Z., Zhu H., Fang, G.G., Walsh, K., Mwamburi, M., **Wolozin,** B., Abdul-Hay, S.O.,

Ikezu, T., Leissring, M.A., Qiu, W.Q., Characterization of Insulin Degrading Enzyme and Other Amyloid-β Degrading Proteases in Human Serum: A Role in Alzheimer's Disease? J Alzheimers Dis. 2012 Jan 9. 29(2):329040, PMID: 22232014 PMCID: PMC3784270

127. Di Domenico, FD, Sultana, R, Ferree, A, Smith, K., Barone, E., Perluigi, M., Coccia, R., Pierce, W., Cai, J., Mancuso, C., Squillace, R., Wiengele, M., **Wolozin, B.** and Butterfield, D.A., Redox Proteomics Analyses of the Influence of Coexpression of Wild Type or Mutated LRRK2 and Tau on *C. elegans* Protein Expression and Oxidative Modification: Relevance to Parkinson Disease. Antioxidants & Redox Signaling, 17(11)1490-506. 2012. PMC3448940.

128. **Wolozin, B**., Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design, *Alzheimer's Research & Therapy* **4**:3 (2012). PMID: 22264400

129. Kim G., Meriin A.B., Gabai V.L., Christians E., Benjamin I., Wilson A., **Wolozin B**., Sherman M.Y., The heat shock transcription factor Hsf1 is downregulated in DNA damage-associated senescence, contributing to the maintenance of senescence phenotype. Aging Cell doi: 10.1111/j.1474-9726.2012.00827 (2012). PMID: 22510478.

130. Goldstein LE, Fisher AM, Tagge CA, Zhang XL, Velisek L, Sullivan JA, Upreti C, Kracht JM, Ericsson M, Wojnarowicz MW, Goletiani CJ, Maglakelidze GM, Casey N, Moncaster JA, Minaeva O, Moir RD, Nowinski CJ, Stern RA, Cantu RC, Geiling J, Blusztajn JK, **Wolozin BL**, Ikezu T, Stein TD, Budson AE, Kowall NW, Chargin D, Sharon A, Saman S, Hall GF, Moss WC, Cleveland RO, Tanzi RE, Stanton PK, McKee AC. Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med. May 16;4(134):134ra60 (2012). PMID: 22593173

131. Youmans, K. and **Wolozin, B.**, TDP-43: A new player in the AD field? Exp. Neurol. (ePub, 2012). PMID: 22691390

132. **Wolozin, B.,** Regulated protein aggregation: Stress granules and neurodegeneration. Mol. Neurodegen. 7(1):56 (2012). PMID: 23164372. (Epub)

133. Ravid, K., **Wolozin, B.,** The scientist's pledge. Academic Medicine 88(6):743 (2013) PMID: 23708595.

134. McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE, Lee HS, Hall G, Wojtowicz SM, Baugh CM, Riley DO, Kubilus CA, Cormier KA, Jacobs MA, Martin BR, Abraham CR, Ikezu T, Reichard RR, **Wolozin** BL, Budson AE, Goldstein LE, Kowall NW, Cantu RC. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2012 Dec 2. 136(1): 43-64. PMID: 23208308

135. Rodriguez-Ortiz, CJ, Hoshino, H, Cheng, D, Liu-Yescevitz, L, Blurton-Jones, M, **Wolozin, B**, LaFerla, FM and Kitazawa, M. Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice. Am J. Pathol. 186:504-15 (2013). PMID: 23747512

136. Liu-Yesucevitz, L., Lin, A, L, Ebata, A., Boon, JY, Reid, W., Xu, Y**,** Kobrin, Murphy, GJ, A, Petrucelli, L and **Wolozin, B**. ALS-linked mutations cause dysfunction of TDP-43-enriched RNA granules J. Neuroscience 34:4167-74 (2014). PMID: 24647938

137. Vanderweyde, T., Youmans, K., Liu-Yesucevitz, L. and **Wolozin, B**., The Role Stress Granules and RNA Binding Proteins in Neurodegeneration, Gerontology 59:524-33 (2013) PMID: 24008580.

138. Boyd, J.D., Lee, P., Feiler, M.S., Zauur, N., Liu, M., Concannon, J., Ebata, A., **Wolozin, B**.*, Glicksman, M.A.* A high content screen identifies novel compounds that inhibit stress-induced TDP-43 cellular aggregation and associated cytotoxicity. J. Biomol. Screening. (2014) 19:44-56. *Co-senior authors. PMID: 24019256

139. Saha, S., Liu-Yesucevitz, L., **Wolozin, B**., Regulation of autophagy by LRRK2 in C. elegans. Neurodegen. Dis. (2013) PMID 24192129

140. Leung A, Nah SK, Reid W, Ebata A, Koch CM, Monti S, Genereux JC, Wiseman RL, **Wolozin B**, Connors LH, Berk JL, Seldin DC, Mostoslavsky G, Kotton DN, Murphy GJ. Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis. Stem Cell Reports. 2013 Oct 31;1(5):451-63. PMID: 24286032

141. Ash PE, Vanderweyde TE, Youmans KL, Apicco DJ, **Wolozin B**., Pathological stress granules in Alzheimer's disease, 2014, Brain Res. 2014 Oct 10;1584:52-8. PMID: 25108040, PMCID: PMC4256948

142. Saha, S., Ash, P.E., Gowda, V., Liu-Yesucevitz, L., Gendi, M., Shirihai, O., Glabe., C., Wolozin, B., Mutations in LRRK2 Potentiate Age-Related Impairment of Autophagic Flux. Mol. Neurodegeneration, 2015 10(1):26. doi: 10.1186/s13024-015-0022-y. PMID: 26159606.

143. **Wolozin, B**., Physiological Proteins Run Amuck: Stress Granules and the Genesis of Neurodegenerative Disease. Discovery Med. 17:47-52 (2014). PMID: 24411700.

144. Dusonchet, J., Li, H., Guillily, M., Stafa, K., Pyenson, N., Liu, M., Derada, C., Glauser, L., Mamais, A., Citro, A., Saha, S., Liu-Yesucevitz, L., Schneider, B.L., Aebischer, P., Yue, Z., Bandopadhyay, R., Glicksman, M., Moore, D.J., Collins, J. J., **Wolozin, B**., A Parkinson's disease gene regulatory network identifies RGS2 as a modulator of LRRK2 activity. Human Mol. Genetics. 2014 23(18):4887-905. PMID: 25071441.

145. Boon, J. Y., Dusonchet, J. and **Wolozin, B**., Interaction of LRRK2 with kinase and GTPase Signaling Cascades. Frontiers in Neuroscience, 2014 doi: 10.3389/fnmol.2014.00064 (ePub) PMID: 25071441.

146. Zhou, Q, Yen, A, Rymarczyk, A, Asai, H, Trengrove, C, Aziz, N, Kirber, M, Ikezu, T, **Wolozin, B**, and Bolotina, B, Impairment of PARK14-dependent Ca^{2+} signaling is a novel trigger and hallmark of Parkinson's disease. Nat. Comm. 2016; 7:10332. doi: 10.1038/ncomms10332.

147. Vanderweyde, T., Apicco, D.J., Youmans-Kidder, K., Ash, P.E.A., Cook, C., da Rocha, E.L., Jansen-West, K., Frame, A.A., Citro, A., Ivanov, P., Abisambra, J.F., Steffen, M., Li,

H., Petrucelli, L., **Wolozin, B.**, Interaction with tau with RNA binding protein TIA1 regulates tau pathophysiology and toxicity**.** Cell Reports 15: 1-12 (2016). PMID: 27160897

148. **Wolozin, B**., Apicco, D., RNA binding proteins and the genesis of neurodegenerative diseases. Adv. Exp. Med. Biol. 2015;822:11-5. PMID: 25416971.

149. Asai, H, Ikezu, S, Tsunoda, S, Medalla, M, Luebke, J, Haydar, T, **Wolozin, B**, Butovsky, O, Kügler, S, Ikezu, T., Mechanisms of microglial and exosome-mediated propagation of pathogenic tau protein in mouse tauopathy models. Nature Neuroscience, 2015 18(11):1584-93. PMID: 26436904

150. Meier, S., Bell, M., Lyons, D., Rodriguez-Rivera, J., Fontaine, S., Ingram, A., Mechas, E., Chen, J., **Wolozin**, **B.**, Levine, H., Zhu, H., and Abisambra, J. Pathological tau promotes neuronal damage by impairing ribosomal function and decreasing protein synthesis". J Neuroscience 2016 36(3):1001-7. PMID: 26791227

151. Ostrowski, S., Shank, S., Sironi, L., **Wolozin, B**., Landreth, G., Zlady, A. Simvastatin inhibits isoprenylation in the brain. Neuroscience 2016 329: 264-72. PMID: 27180285

152. Russo A., Scardigli, R., La Regina F., Murray E.M., Romano, N., Dickson D.W., **Wolozin, B**., Cattaneo, A., Ceci M., Increased Cytoplasmic TDP-43 Reduces Global Protein Synthesis by Interacting with RACK1 on Polyribosomes, Human Molecular Genetics 2016 15;26(8):1407-1418.

153. Kuwahara T., Inoue K., D'Agati V.D., Fujimoto T., Eguchi T., Saha S., **Wolozin B.**, Iwatsubo T., Abeliovich A., LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. Sci Rep. 2016 6:29945. PMCID: PMC4947924

154. Maziuk, B., Ballance, H.I., **Wolozin, B**., Dysregulation of RNA binding protein aggregation in neurodegenerative disorders. Frontiers in Molecular Neuroscience 2017 Apr 4;10:89. doi: 10.3389/fnmol.2017.00089

155. Ash, P.E., Stanford, E.A., Al Abdulatif, A., Ramirez-Cardenas, A., Ballance, H.I., Boudeau, S., Jeh, A., Murithi, J.M., Tripodis, Y., Murphy, G.J., Sherr, D.H., **Wolozin, B**., Dioxins and Related Environmental Contaminants Increase TDP-43 Levels, Molecular Neurodegeneration. 2017, 12(1):35. doi: 10.1186/s13024-017-0177-9

156. Zhu H, Xue X, Wang E, Wallack M, Na H, Hooker JM, Kowall N, Tao Q, Stein TD, **Wolozin B,** Qiu WQ. Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease. Neuropharmacology. 2017 Mar 28. pii: S0028-3908(17)30121-1. doi: 10.1016/j.neuropharm.2017.03.030.

157. **Wolozin B,** Sotiropoulos I. Dendritic TAU-telidge, EBioMedicine. 2017 May 17. pii: S2352-3964(17)30210-4

158. Sindi S, Ngandu T, Hovatta I, Kåreholt I, Antikainen R, Hänninen T, Levälahti E, Laatikainen T, Lindström J, Paajanen T, Peltonen M, Khalsa DS, **Wolozin B**, Strandberg T, Tuomilehto J, Soininen H, Kivipelto M, Solomon A; FINGER study group. Baseline

Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial., J Alzheimers Dis. 2017;59(4):1459-1470.

159. Apicco, D.J., Ash, P.E.A., Maziuk, B., LeBlang, C., Medalla, M., Al Abdullatif, A., Ferragud Faus, A., Botelho, E., Ballance, Dhawan, U., Boudeau, S., Lourdes-Cruz, A., Kashy, D., Wong, A., Goldberg, L.R., Yazdani, N., Zhang, C., Ung, C., Kanaan, N.M., Tripodis, Y., Ikezu, T., Cottone, P., Leszyk, J., Li, H., Luebke, J., Bryant, C.D., **Wolozin, B.,** Reducing TIA1 protects against tau-mediated neurodegeneration in vivo. Nature Neuroscience, 2018 21(1):72-80. PMC5745051

160. Silva, J.M., Rodrigues, S., Sampaio-Marques, B., Gomes, P., Neves-Carvalho, A., Dioli, C., Soares-Cunha, C., Takashima, A., Ludovico, P., **Wolozin, B**., Sousa, N., Sotiropoulos, I., Dysregulation of autophagy and stress-granule related proteins in stress-driven tau pathology. Cell Death and Differentiation. 2019 26(8):1411-27, doi: 10.1038/s41418-018-0217-1, PMID: 30442948. PMCID: PMC6748085

161. Li, D., Wang, L., Maziuk, B.F., Yao, X., **Wolozin, B.,** Yong Ku Cho. Directed evolution of a picomolar affinity, high-specificity antibody fragment targeting phosphorylated tau. JBC 2018 J Biol Chem. 2018 293(31):12081-94. doi: 10.1074/jbc.RA118.003557. PMID: 29899114.

162. Maziuk BF, Apicco DJ, Cruz AL, Jiang L, Ash PEA, da Rocha EL, Zhang C, Yu WH, Leszyk J, Abisambra JF, Li H, **Wolozin B**. RNA binding proteins co-localize with small tau inclusions in tauopathy. Acta Neuropathol Commun. 2018 Aug 1;6(1):71. doi: 10.1186/s40478-018-0574-5. PMID: 30068389.

163. Ruan QT, Yazdani N, Beierle JA, Hixson KM, Hokenson KE, Apicco DJ, Luttik KP, Zheng K, Maziuk BF, Ash PEA, Szumlinski KK, Russek SJ, **Wolozin B**, Bryant CD. Changes in neuronal immunofluorescence in the C- versus N-terminal domains of hnRNP H following D1 dopamine receptor activation. Neurosci Lett. 2018 Jul 9;684:109-114. doi: 10.1016/j.neulet.2018.07.015. PMID: 30003938

164. Boeynaems S, Alberti S, Fawzi NL, Mittag T, Polymenidou M, Rousseau F, Schymkowitz J, Shorter J, **Wolozin B**, Van Den Bosch L, Tompa P, Fuxreiter M. Protein Phase Separation: A New Phase in Cell Biology. Trends Cell Biol. 2018 Jun;28(6):420-435. doi: 10.1016/j.tcb.2018.02.004. PMID: 29602697

165. Jiang, L., Ash, P. E. A., Maziuk, B. F., Balance, S., Boudeau, Abdullatif, A. A., Orlando, M., Petrucelli, L., Ikezu, T., **Wolozin, B.,** TIA1 regulates the generation and response to toxic tau oligomers. Acta Neuropathologica Scandinavia. 2019, 137(2):259-77. PMID 30465259. doi.org/10.1007/s00401-018-1937-5.

166. Li, D., Wang, L, Maziuk, B.F., Yao, X., **Wolozin, B**., Cho, Y.K., Directed evolution of a picomolar-affinity, high-specificity antibody targeting phosphorylated tau. J. Biol. Chem. 2018, 293(31):12081-94, doi: 10.1074/jbc.RA118.003557, PMID: 2989914, PMCID: PMC6078456

167. **Wolozin, B.,** Disrupted in Dementia, Biological Psychiatry, 2018; 84:474-5. DOI: 10.1016/j.biopsych.2018.07.016, PMID: 30176990

168. Ash, P. E. A., Dhawan, U., Boudeau, S., Lei, S., Carlomagno, Y., Knobel, M., Al Mohanna, L., F., A., Boomhower, S., R., Newland, M., C., Sherr, D., H., **Wolozin., B**., Heavy metal neurotoxicants induce ALS-linked TDP-43 pathology, Toxicological Sciences, 2019 167(1):105-15. PMID 30371865. doi: 10.1093/toxsci/kfy267. PMCID: PMC6317426

169. **Wolozin, B.,** Ivanov, P., Stress granules and neurodegeneration. Nature Reviews Neuroscience, 2019. 20(11): 649-66. PMCID: PMC6986315doi: 10.1038/s41583-019-0222-5.

170. **Wolozin, B.,** The evolution of phase separated TDP-43 in stress. Neuron. 2019 Apr 17; 102(2):265-267. PMID: 30998893

171. Gan Q, Yao H, Na H, Ballance H, Tao Q, Leung L, Tian H, Zhu H, **Wolozin B**, Qiu WQ. Effects of Amylin Against Amyloid-β-Induced Tauopathy and Synapse Loss in Primary Neurons. J Alzheimer's Dis. 2019 Jul 12. 70(4):1025-40. doi: 10.3233/JAD-190161. PMID: 31306122, PMC6833957.

172. Apicco, D. J., Zhang, C., Maziuk, B.F., Jiang, L., Balance, H.I., Boudeau, S., Ung, C., Li, H. ¶, **Wolozin, B**., Dysregulation of RNA splicing in tauopathies. Cell Reports 2019 Dec. 24. 29:4377-4388. PMID: 31875547. doi: 10.1016/j.celrep.2019.11.093.

173. Ruan QT, Yazdani N, Blum BC, Beierle JA, Lin W, Coelho MA, Fultz EK, Healy AF, Shahin JR, Kandola AK, Luttik KP, Zheng K, Smith NJ, Cheung J, Mortazavi F, Apicco DJ, Ragu Varman D, Ramamoorthy S, Ash PEA, Rosene DL, Emili A, **Wolozin B**, Szumlinski KK, Bryant CD, A mutation in Hnrnph1 that decreases methamphetamine-induced reinforcement, reward, and dopamine release and increases synaptosomal hnRNP H and mitochondrial proteins. J. Neuroscience 2019 Nov 8. pii: 1808-19. doi: 10.1523/JNEUROSCI.1808-19.2019. [Epub ahead of print] PMID: 31704785].

174. LeBlang, CJ, Medalla, M, Nicoletti, NW, Hays, EC Zhao, J, Shattuck, J, Cruz, AL, **Wolozin, B** and Luebke, JI, Reduction of the RNA Binding Protein TIA1 exacerbates neuroinflammation in tauopathy. Frontiers Neuroscience 2020, doi: 10.3389/fnins.2020.00285. PMID: 32327969. PMCID: PMC7161592.

175. Pourhaghighi, R, Ash, PEA, Phanse, S, Goebels, F, Hu, LZM, Chen, S, Zhang, Y, Wierbowski, SD, Boudeau, S, Moutaoufik, MT, Malty, RH, Malolepsza, E, Tsafou, K, Nathan, A, Cromar, G, Guo, H, Abdullatif, AA, Apicco, DJ, Becker, LA, Gitler, AD, Pulst, SM, Youssef, A, Hekman, R, Havugimana, PC, Ratti, A, Bryant, CD, John Parkinson, J, Lage, K, Babu, M, Yu, H, Bader, GD, **Wolozin, B**, and Emili, A, BraInMap elucidates the macromolecular connectivity landscape of mammalian brain. Cell Syst. 2020 Apr 22;10(4):333-350.e14. doi: 10.1016/j.cels.2020.03.003. PMID: 32325033. PMCID: PMC7938770

176. Li M, Reisman J, Morris-Eppolito B, Qian SX, Kazis LE, **Wolozin B**, Goldstein LE, Xia W., Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury. Alzheimers Res Ther. 2020 Mar 27;12(1):33. doi: 10.1186/s13195-020-00589-3. PMID: 32220235

177. Ikezu T, Koro L, **Wolozin B**, Farraye FA, Strongosky AJ, Wszolek ZK., Crohn's and Parkinson's Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in

Human CD14+ Blood Monocytes Ex Vivo. J Neuroimmune Pharmacol. 2020 Mar 16. doi: 10.1007/s11481-020-09909-8. PMID: 32180132

178. Reiss, AB, Glass, AD, Wisniewski, T, **Wolozin, B**, Gomolin, IH, Pinkhasov, A, De Leon, J, Stecker, MM, Alzheimer's disease: many failed trials, so where do we go from here? J Investig Med. 2020 Jul 21;jim-2020-001297. doi: 10.1136/jim-2020-001297, PMID: 32699179.

179. Ruan QT, Yazdani N, Reed ER, Beierle JA, Peterson LP, Luttik KP, Szumlinski KK, Johnson WE, Ash PEA, **Wolozin B**, Bryant CD, 5' UTR variants in the quantitative trait gene Hnrnph1 support reduced 5' UTR usage and hnRNP H protein as a molecular mechanism underlying reduced methamphetamine sensitivity. FASEB J. 2020, DOI: 10.1096/fj.202000092R, PMID: 32401417

180. Jiang, L, Zhao, J, Cheng, JX, **Wolozin B**, Tau Oligomers and Fibrils Exhibit Differential Patterns of Seeding and Association with RNA Binding Proteins, Frontiers in Neurology 2020, 11:579434, doi: 10.3389/fneur.2020.579434. PMID: 33101187

181. Hekman RM, Hume AJ, Goel RK, Abo KM, Huang J, Blum BC, Werder RB, Suder EL, Paul I, Phanse S, Youssef A, Alysandratos KD, Padhorny D, Ojha S, Mora-Martin A, Kretov D, Ash P, Varma M, Zhao J, Patten JJ, Villacorta-Martin C, Bolzan D, Perea-Resa C, Bullitt E, Hinds A, Tilston-Lunel A, Varelas X, Farhangmehr S, Braunschweig U, Kwan JH, McComb M, Basu A, Saeed M, Perissi V, Burks EJ, Layne MD, Connor JH, Davey R, Cheng JX, **Wolozin BL**, Blencowe BJ, Wuchty S, Lyons SM, Kozakov D, Cifuentes D, Blower M, Kotton DN, Wilson AA, Mühlberger E, Emili A., Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2. Mol Cell, 2020, PMID: 33259812, PMCID: PMC7674017, doi: 10.1016/j.molcel.2020.11.028.

182. Sindi S, Solomon A, Kåreholt I, Hovatta I, Antikainen R, Hänninen T, Levälahti E, Laatikainen T, Lehtisalo J, Lindström J, Paajanen T, Peltonen M, Singh Khalsa D, **Wolozin B**, Strandberg T, Tuomilehto J, Soininen H, Ngandu T, Kivipelto M; FINGER Study Group. Telomere length change in a multidomain lifestyle intervention to prevent cognitive decline: a randomized clinical trial. J Gerontol A Biol Sci Med Sci., 2020, PMID: 33175128, doi: 10.1093/gerona/glaa279.

183. Webber, C.J, Lei, S. E., **Wolozin, B**., The pathophysiology of neurodegenerative disease: Disturbing the balance between phase separation and irreversible aggregation, Prog Mol Biol Transl Sci., 2020;174:187-223. PMID: 32828466, PMC8265525, doi: 10.1016/bs.pmbts.2020.04.021

184. Basu, A., Ash, P. E. A., **Wolozin, B**., Emili, A., Protein Interaction Network Biology in Neuroscience. Proteomics. 2021, 21(3-4):e1900311. PMID: 33417854.

185. Ash, P. E. A., Lei, S., Shattuck, J., Boudeau, S., Carlomagno, Y., Mashimo, B. L., Socorro, G., Al-Mohanna, L. F. A., Jiang, L., Öztürk, M. M., Knobel, M., Ivanov, P., Petrucelli, L., Wegmann, S., Kanaan, N. K., **Wolozin. B**., TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau. Proc Natl Acad Sci U S A. 2021, 118(9):e2014188118. PMID: 33619090. PMC7936275.

186. Jiang, L., Lin, W., Zhang, C., Ash, P. E. A., Verma, M., Kwan, J., van Vliet, E., Yang, Z., Cruz, A. L., Boudeau, S., Maziuk, B. F., Lei, S., Song, J., Alvarez, V. E., Hovde, S., Abrisambra, J. F., Kayed, R., Hovde, S., Abisambra, J. F., Kuo, M. H., Kanaan, N., Murray,

M. E., Crary, J. F., Zhao, J., Cheng, J., X., Petrucelli, L., Li, H., Emili, A., **Wolozin, B**., Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy. Mol. Cell (2021), S1097-2765(21)00622. PMID: 34453888 DOI: 10.1016/j.molcel.2021.07.038.

Commentary in:
Nat Rev Mol Cell Biol. 2021 Oct;22(10):650 and
Alzforum:
https://www.alzforum.org/news/research-news/methylated-rna-new-player-tau-toxicity

187. Rickner[#], H.D., Jiang[#], L., Hong, R., O'Neill, N. K., Mojica, C. A., Snyder, B., J., Zhang, L., Shaw, D., Medalla, M., **Wolozin*, B**., Cheng*, C. S., Single cell transcriptomic profiling of a neuron-astrocyte assembloid tauopathy model. (2022), 13(1):6275, doi: 10.1038/s41467-022-34005-1. PMCID: PMC9587045.

188. Puri[#], S., Hu[#], J., Sun, Z., Lin, M., Stein, T., Farrer, L.A., Wolozin*, B. and Zhang*, X., Identification of circRNAs linked to Alzheimer's disease and related dementias. Alzheimer & Dementia, 2023, doi: 10.1002/alz.12960. PMID: 36795937

189. Jiang[#], L., Chakraborty[#], P., Libera, J., Blair, L.J., Wolozin*, B., Zweckstetter*, M., Chaperoning of specific tau structure by immunophilin FKBP12 regulates the neuronal resilience to extracellular stress, Sci. Advances, 2023, doi: 10.1126/sciadv.add9789. PMID: 36724228.

Commentary in:
Alzforum:
https://www.alzforum.org/news/research-news/chaperone-fkbp12-shields-tau-aggregation

Books and Book Chapters

190. Takashima, Buee and **Wolozin**, Tau Biology, (Springer Book, Eds: Takashima, Buee and **Wolozin**). Adv. Exp. Biol., 2019.
191. Cruz, A.,Verma, M., **Wolozin, B**., The pathophysiology of tau and stress granules in disease. In "Tau Biology" (Springer, Eds: Takashima, Buee and **Wolozin**). 2019. Adv Exp Med Biol. 2019; 1184:359-372. PMID: 32096049, PMC8265570.
192. Vanderweyde, T., **Wolozin, B**., RNA binding proteins in health and disease. In "Neuroimmune Pharmacology" (Springer, Eds: Ikezu and Gendelman). 2016
193. **Wolozin, B**., Neurodegeneration: Twists, Turns and Tangles. In "Discoveries in Modern Science: Exploration, Invention, Technology" (McMillan Reference, Cengage Learning, Farmington Hills, MI) 2014.

PUBLICATIONS (Lay Audience)

1. Wolozin, B., The Art of Persuasion in Politics, Skeptical Inquirer, 31(1), 2007.
2. Wolozin, B., Live Report: Rally to Restore Sanity and/or Fear, a Plea for Reason, Skeptical Inquirer, 35(2), 2011.

INVENTIONS

1989 Identification and characterization of neuronal antigen A68 (patent approved 1998; Patent 5,811,310)

1991 Human Olfactory Neuron Cultures (patent approved 1998; Patent: 5,869,266)

1998 Methods for treating, preventing, and reducing the risk of onset of Alzheimer's disease using an HMG CoA Reductase Inhibitor (patent approved 2002; Patent 6,472,421)

2000 Method of controlling and regulating α-synuclein aggregation: inhibition and induction. (Patent approved 2001; Patent 6,780,971).

2011 Wolozin, B., Identification of Compounds that disperse TDP-43 inclusions. Patent Application. PCT/US12/38861 (2012).

2015 Wolozin, B., Nucleic acid based TIA1 inhibitors. Application #: 62/241535

2021 Wolozin, B., Cheng, C., Rickner, H., Jiang., Synthetic Brain Organoids and Uses Thereof, Application #: 63/314,585